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Abstract 
Ebola virus disease (EVD) is a severe illness caused by infection with Ebola virus (EBOV) 
which causes sporadic outbreaks in African countries, the last one taking place in West Africa 
and affecting over 28000 people. Even though several decades have passed since the 
description of the first EVD cases, there are still many unanswered questions regarding the 
involvement of the human immune response in the pathophysiology of EVD. Research in this 
field is challenging because of the requirement of biosafety level 4 containment and the 
scarcity of human data.  
During the last EVD outbreak in West Africa, we had the opportunity to establish an 
immunology lab at Donka hospital in Conakry, Guinea where we collected and analysed 
leftover blood samples from patients diagnosed by the European Mobile Laboratory. With 
the use of benchtop multiparametric flow cytometry and subsequent analysis in the 
biosafety level 4 laboratory in Hamburg, we evaluated the kinetics and phenotype of 
antigen-presenting cells as well as T cells with the goal to identify immune biomarkers of 
disease outcome. Our approach was to utilize flow cytometry to characterize cell profiles in 
blood as well as immunogenetics, in particular analysis of the T-cell receptor clonotypes and 
HLA polymorphisms. Immune data was then correlated with clinical and epidemiological 
findings to try to detect potential predictors of outcome and targets for immunotherapy.  
Our observations highlight the importance of CD16+ monocytes in the innate immune 
response to EBOV infection and in viral clearance. Additionally, we could identify a 
dysregulation of the adaptive immune response in fatal cases, characterised by the 
upregulation of the T cell inhibitory markers CTLA-4 and PD-1 and the inability to control 
viral replication. These results identify CD16+ monocytes and the regulatory pathways of T 
cell responses as potential targets for post-exposure EVD immunotherapy. Moreover, our 
immunogenetics study evidenced the relevance of the expression of various HLA alleles and 
the activation of a T cell response through a broad and diverse T cell receptor repertoire in 
improved disease outcome.  
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Zusammenfassung 
Ebolafieber (EVD) ist eine schwerwiegende Krankheit, die ausgelöst wird durch die Infektion 
mit Ebola Virus (EBOV), welches sporadische Ausbrüche in afrikanischen Ländern verursacht. 
Der letzte Ausbruch in West Afrika zählte 28.000 Fälle. Obwohl seit der ersten Beschreibung 
eines EVD Falles mehrere Jahrzehnte vergangen sind, bestehen noch viele unbeantwortete 
Fragen bezüglich der Rolle des menschlichen Immunsystems in der Pathophysiologie von 
EVD. Forschung in diesem Gebiet gestaltet sich wegen der Notwendigkeit für ein 
Biosicherheitsstufe 4 Containment und der Rarität menschlicher Daten als schwierig.   
Während des letzten EVD Ausbruchs in West Afrika hatten wir die Möglichkeit ein 
Immunologie-Labor im Donka Krankenhaus in Conakry, Guinea, zu etablieren, wo wir 
übriggebliebenes Blutprobenmaterial von Patienten, die durch das European Mobile 
Laboratory diagnostiziert wurden, sammelten und analysierten. Mittels multiparametrischer 
Durchflusszytometrie vor Ort und subsequenter Analyse im Biosicherheitsstufe 4 Labor in 
Hamburg evaluierten wir die Kinetik und den Phänotyp von antigenpräsentierenden Zellen 
und T-Zellen mit dem Ziel Immun-Biomarker für den Krankheitsausgang zu identifizieren. 
Hierfür verwendeten wir Durchflusszytometrie um Zell Profile im Blut zu charakterisieren, 
sowie Immungenetik, speziell die Analyse des T-Zell Rezeptor Klonotyps und von HLA 
Polymorphismen. Folgend untersuchten wir Korrelationen zwischen Immunparametern und 
klinischen und epidemiologischen Werten um potenzielle Prädiktoren für Krankheitsausgang 
sowie Ziele für Immuntherapie zu detektieren.  
Unsere Beobachtungen heben die wichtige Rolle von CD16 Monozyten in der angeborenen 
Immunantwort auf EBOV und für die Viruselimination hervor. Zusätzlich konnten wir in 
fatalen Erkrankungsfällen Dysregulation der adaptiven Immunabwehr beschreiben, 
charakterisiert durch Hochregulierung der inhibierenden T-Zell Marker CTLA-4 und PD-1 und 
durch das Unvermögen virale Replikation zu kontrollieren. Diese Resultate identifizieren 
CD16 Monozyten und die regulatorischen Signalwege der T-Zell Antwort als potenzielle Ziele 
für eine EVD Immuntherapie nach Virusexposition. Darüber hinaus zeigte unsere 
Immungenetik-Studie in Fällen mit besserem Krankheitsausgang die Relevanz der Expression 
verschiedener HLA Allele und die Aktivierung einer T-Zell Antwort basierend auf einem 
breiten und vielfältigen T-Zell Rezeptor Repertoire.  
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Introduction  
Ebola Virus 
Ebola virus (EBOV) is a member of the Ebolavirus genus in the family Filoviridae and in the 
order of the Mononegavirales. Four other virus species have been identified in the 
Ebolavirus genus: Bundibugyo (BDBV), Sudan (SUDV), Reston (RESTV) and Taï Forest 
ebolavirus (TAFV) (King et al. 2012). The first two, together with EBOV, have been associated 
with large outbreaks affecting several African countries while RESTV has only been shown to 
be pathogenic in non-human primates (Miranda & Miranda 2011).  
Marburgvirus and Cuevavirus are two other genera in the Filoviridae family which include 
the Marburg virus (MARV) and the Lloviu virus (LLOV) respectively. 
This thesis is focused in the study of EBOV.  
 
Molecular characterization of EBOV 
EBOV is an enveloped, non-segmented, negative-stranded RNA virus which forms particles of 
about 14000 nm long and 80 nm wide with the characteristic filamentous morphology of the 
Filoviridae virus family (Figure 1) (Regnery et al. 1980; Kiley et al. 1982). The EBOV genome is 
relatively small with 19 kb of length and contains seven genes that encode for the NP, VP35, 
VP40, GP, VP30, VP24 and L proteins (Feldmann & Klenk 2004). The glycoprotein GP is a 
surface protein which plays an important role in viral entry, through receptor binding and 
membrane fusion, and in pathogenicity (Marzi et al. 2006; Volchkova et al. 2015). sGP is a 
soluble protein also encoded by the GP gene which is secreted by infected cells (Volchkov et 
al. 1995). The matrix protein VP40 is essential for viral particle formation and is also involved 
in viral budding (Noda et al. 2002; Harty et al. 2000). The viral proteins VP35 and VP24 were 
identified as antagonists of IFN production and signaling, respectively (Basler et al. 2000; 
Reid et al. 2006). The nucleoprotein NP together with VP30, VP35 and the RNA-dependent 
RNA polymerase L are required for replication and transcription of the virus (Mühlberger et 
al. 1999). 
9 
 
 
Figure 1. EBOV morphology and molecular characterization. Left: electron microscopy image of 
EBOV (Mahanty & Bray 2004). Right: schematic representation of an EBOV virion and its proteins 
(image from http://viralzone.expasy.org/all_by_species/207.html 2017). 
 
Historical overview of Ebola virus disease (EVD) outbreaks 
The first documented outbreak of Ebola virus disease (EVD) formerly called Ebola 
hemorrhagic fever was in 1976 in northern Zaire, now Democratic Republic of the Congo 
(DRC) and later that same year in southern Sudan (Deng et al. 1978; Johnson et al. 1978). 
Since then the virus has reemerged during several outbreaks exclusively in Africa with the 
last one taking place from March 2014 to March 2016 and affecting for the first time West 
African countries including Guinea, Sierra Leone, Liberia and Nigeria. In addition, sporadic 
cases took place in African and non-African countries (Figure 2). The West African outbreak 
had an unprecedented magnitude with over 28000 cases and caused over 11000 deaths 
(World Health Organization 2016). The WHO declared the end of this outbreak in West 
Africa in January 2016. Since then, sporadic cases attributed to sexual transmission have 
occurred (Mate et al. 2015).  
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Figure 2. Distribution map of cases of Ebola virus disease in Africa from 1976 until 2016. Outbreaks 
are indicated by number of cases reported and Ebolavirus species. Outbreaks caused by EBOV are 
indicated in red (image from https://www.cdc.gov/vhf/ebola/outbreaks/history/distribution-
map.html). 
 
Ebola virus disease 
The case-fatality rate of EVD can be as high as 90% and varies between 45-90% depending 
on the outbreak. The incubation period in humans is 2 to 21 days with an average of 10 days 
(Pattyn 1977; Feldmann & Geisbert 2011). The initial symptoms are quite unspecific and 
include flu like symptoms such as fever, fatigue, muscle pain and headache. As the disease 
progresses more severe symptoms may appear such as vomiting, diarrhea, shortness of 
breath, edema, rash, confusion and coma, indicating a systemic infection affecting the 
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digestive, respiratory, vascular and nervous systems (Kortepeter et al. 2011). In previous 
outbreaks, hemorrhagic signs such as bleeding and diffused intravascular coagulopathy (DIC) 
were associated with disease severity and hypovolemic shock and multi-organ failure were 
identified as the cause of death (Pattyn 1977; Feldmann & Geisbert 2011). However, 
bleeding was rarely observed during the last EVD outbreak in West Africa and fatal outcome 
was mainly associated with elevated fever, dizziness, diarrhea and weakness (Schieffelin et 
al. 2014). These observations lead to the modification in the disease moniker from Ebola 
hemorrhagic fever to Ebola virus disease. 
Because of the high severity and mortality of the EVD, the elevated transmission rate and 
the lack of an effective vaccine or specific treatment, EBOV is classified as a highly 
pathogenic virus to be handled in biosafety level 4 (BSL-4) containment laboratories. This 
constrains research on EBOV, together with the fact that most of the past outbreaks took 
place in relatively isolated rural areas. Another reason that has made studies on EBOV 
pathophysiology and immunity challenging is the lack of adequate small animal models that 
are both susceptible and immunocompetent.  
 
Animal reservoir 
EVD is a zoonosis which means that it can naturally be transmitted from a vertebrate animal 
to humans. Although much effort has been made to identify the animal reservoir of EBOV 
this information is currently unknown. Non-human primates that are distributed in Ebola-
affected countries have been also shown to be highly susceptible to infection (Leroy et al. 
2004; Walsh et al. 2003). Spillover from these species to humans have been linked to the 
initiation of human outbreaks (Groseth et al. 2007). Other small mammals like duikers and 
pigs can also be infected with EBOV and could also represent a source of infection for 
humans. Duiker carcasses tested positive for EBOV around an area affected by an EVD 
outbreak in Gabon. (Leroy et al. 2004) In addition, pigs can be experimentally infected and 
show pathogenicity as well as capacity to transmit the virus (Kobinger et al. 2011; Weingartl 
et al. 2012).  
Egyptian fruit bats (Rousettus aegyptiacus) were pinpointed as a natural reservoir of 
filoviruses when MARV was isolated from their tissues (Pourrut et al. 2009). MARV 
transmission from Egyptian fruit bats to humans has already been documented and 
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epidemiological studies present a strong link between fruit bats and humans at the time of a 
MARV outbreak (Amman et al. 2012). Today, there is still limited evidence showing that 
EBOV outbreaks in humans could result from exposure to infected bats (Leroy et al. 2009). 
After unsuccessfully testing of several animal species for the presence of EBOV finally three 
species of bats were identified as the most likely candidates to be a reservoir species for the 
virus. Although no infectious virus was ever isolated from these animals, serological tests in 
bat species Hypsignathus monstrosus, Epomops franqueti and Myonycteris torquata 
detected the presence of immunoglobulin G (IgG) specific for EBOV. Moreover, viral RNA 
was detected in both the liver and spleen from other bats from the same population (Leirs et 
al. 1999; Leroy et al. 2005).  
 
Human to human transmission 
Transmission of EBOV to and among humans occurs through contact with infected body 
fluids and fomites (Bausch et al. 2007). With some exception, most outbreaks have been 
initiated by a single spillover event followed by intense human-to-human transmission, 
although multiple spillover events have also been described (Baize et al. 2014; Ksiazek et al. 
1999; Leroy et al. 2004). Nosocomial transmission or virus spread through traditional African 
practices such as funeral rituals have contributed to amplify outbreaks in the past, and have 
been paramount also during the West African outbreak (Zaki et al. 1999; Baize et al. 2014). 
Persistence of the virus in some human tissues long after recovery can also be a source of 
transmission. During the last EVD outbreak in West Africa, EBOV RNA was detected several 
weeks after recovery from EVD in patient’s semen, ocular fluid, sweat, urine, vaginal 
secretions, feces and breast milk (Uyeki 2016; Mate et al. 2015; Diallo et al. 2016). 
Moreover, viral particles could be isolated from semen, ocular fluid, saliva and breast milk 
and for the first time the sexual transmission of EBOV was reported (Uyeki 2016; Varkey et 
al. 2015; Bausch et al. 2007; Diallo et al. 2016). 
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Figure 3. Transmission dynamics of EBOV. Potential reservoir dynamics are shown in blue, spillover 
events from reservoir species are shown in red and further human to human transmission are shown 
in orange. The role of vectors shown in dashed lines is unlikely since EBOV replication in arthropod 
cell lines was unsuccessful (Olival & Hayman 2014). 
 
Animal models 
Non-human primates best reproduce human EVD and so they have been extensively used 
for research on EBOV pathogenesis as well as therapies and vaccines  (Thomas W. Geisbert 
et al. 2003; Hensley et al. 2002; Sullivan et al. 2003). Ethical, practical and economic reasons 
however restrict the use of NHP on immunological studies, since these would require a large 
number of animals and there is still a lack of necessary reagents. Moreover, BSL4 
laboratories equipped to perform these kind of research are limited. This has motivated the 
development of small animal models like mice, which are easier to handle and allow the 
research of specific genetic factors on pathogenesis and the manipulation of specific 
immune cell populations to investigate their importance for the immune response. 
Adult immunocompetent mice are resistant to EBOV infection. EBOV was adapted to the 
mouse species through its sequential passage in newborn mice. This mouse-adapted EBOV 
(maEBOV) strain induced a disease in mice similar to that observed in NHP with the wild type 
virus (Bray et al. 1998). The adaptation of the virus entails genomic mutations which have 
helped identify molecular mechanisms involved in EBOV pathogenesis. However mice are 
only susceptible to maEBOV when receiving an intraperitoneal inoculation and some 
differences are observed when comparing to the disease in humans or NHP. For the study of 
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non-adapted EBOV, mice with defects in the innate or adaptive immune response such as 
IFNAR-/- or STAT-/- mice are used (Bray 2001; Raymond et al. 2011). These 
immunocompromised mouse models are susceptible to infection with wild type EBOV and 
shed some light on the importance of the IFN-I response in protection against EBOV 
infection. Wild type mice are susceptible to wild type EBOV infection when treated with 
antibodies against murine IFN-α/β receptor suggesting that a critical mechanism for EBOV 
pathogenesis is the viral inhibition of IFN-I responses (Bray 2001). 
Recently, a humanized mouse model was shown to reproduce key features of human EBOV 
pathogenesis (Lüdtke et al. 2015). In this study the hematopoietic system of NSG mice was 
reconstituted with transplanted human hematopoietic stem cells which allowed the 
development of an adaptive human immune system in the animals, making it an appropriate 
model for investigating the kinetics of the human immune response to EBOV infection. 
Another highly valuable mouse model for the study of human immune responses during EVD 
is the humanized bone marrow/liver/thymus (hu-BLT) mouse (Bird et al. 2016). When 
infected with wild type EBOV, these mice mimic the immune responses observed during 
human EVD such as elevated proinflammatory cytokines levels. Both of these humanized 
mouse models have the advantage of reproducing human donor variability. Some limitations 
still exist for these models, including the risk of graft versus host disease and the poor 
understanding of the interaction of murine and human cells. Nevertheless they remain a 
valuable tool to determine correlates of immune protection in EVD and for the development 
of EBOV vaccines and therapeutics.  
 
Immune response 
When the human body encounters an infectious agent the immune response is its first line 
of defense. The first reaction is the innate immune response which is immediate and 
nonspecific, followed by the adaptive immune response which is acquired and antigen 
specific. In the case of EBOV infection antigen presenting cells, such as dendritic cells, are 
main targets of infection. EBOV is capable of blocking the IFN-I response in these cells, a key 
mechanism of the innate immune response. As a consequence their maturation is arrested 
as well as their capacity to prime naïve T cells for the activation of the adaptive immune 
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response. In this section I will introduce the basic aspects of a human immune response and 
how it is affected by EBOV infection. 
 
EBOV portals of entry 
EBOV enters the human body through the mucosa or the skin (Feldmann & Geisbert 2011). 
Immunohistochemistry and electron microscope analysis showed that the virus has a wide 
cell tropism: endothelial cells, monocytes, macrophages, dendritic cells, hepatocytes, 
fibroblasts, adrenal cortical cells and epithelial cells are actively infected by EBOV (Zaki et al. 
1999; Ryabchikova et al. 1999). 
EBOV infection of cells is dependent on its binding to several cell-surface molecules. These 
receptors include C-type lectins such as the dendritic cell specific ICAM-3 grabbing non-
integrin (DC-SIGN) or the liver/lymph node-SIGN (L-SIGN) (Alvarez et al. 2002). Another 
important molecule for EBOV attachment to the host cells is the T-cell immunoglobulin and 
mucin domain 1 (TIM-1) which is expressed on several mucosal epithelial surfaces 
(Kondratowicz et al. 2011). EBOV then enters the cells through a macropinocytosis 
mechanism mediated by the viral glycoprotein interacting with the endo/lysosomal 
cholesterol transporter protein Niemann-Pick C1 (NPC1) (Saeed et al. 2010; Nanbo et al. 
2010; Lee & Saphire 2009; Côté et al. 2011; Carette et al. 2011).  
Infection of cells by EBOV leads to cell death and consequently to necrosis of the affected 
tissue (Mahanty & Bray 2004). 
 
Innate antiviral immune response 
Cells that play a chief role in the innate immune response at the sites of infection are 
dendritic cells, macrophages, neutrophils, monocytes and natural killer (NK) cells, among 
others. Phagocytic macrophages engulf circulating pathogens and are activated to secrete 
cytokines which recruit monocytes and neutrophils to the site of infection. These two cell 
populations mediate proinflammatory responses while NK cells are important for lysing 
infected cells. 
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The innate immune response is activated when specific host-germline encoded receptors 
called pattern recognition receptors (PRRs) sense structures conserved among pathogens 
called pathogen associated molecular patterns (PAMPs), such as dsRNA. There are four 
different families of PRRs: transmembrane proteins such as the Toll-like receptors (TLRs) and 
the C-type lectin receptors (CLRs) and cytoplasmic proteins such as the Retinoic acid-
inducible gene (RIG)-I-like receptors (RLRs) and the NOD-like receptors (NLRs). These PRRs 
are expressed on innate immune cells like macrophages and dendritic cells although they are 
also found on other immune cells that also contribute to the response. The activation of 
these receptors causes the phosphorylation of IFN regulatory factor (IRF) 3 which dimerizes 
and translocates to the nucleus where it induces the expression of IFN-I. The binding of IFN-I 
to the interferon-α/β receptor (IFNAR) in an autocrine and paracrine way activates Janus 
kinase (JAK) protein tyrosine kinases that in turn phosphorylate the signal transducer and 
activator of transcription STAT1 and STAT2. These interact with IRF9 to form the 
transcription factor complex IFN-stimulated gene factor 3 (ISGF3) which translocates to the 
nucleus and binds to IFN-stimulated response elements (ISRE) which lead to the expression 
of many IFN-inducible antiviral genes (Ivashkiv & Donlin 2014). This response is fundamental 
for the protection of host cells against viral infections as well as for the maturation of 
dendritic cells and the subsequent activation of acquired immunity. Some of the IFN-induced 
genes are protein kinase R (PKR) which suppresses the proliferation of infected cells and 2’-
5’-oligoadenylate synthase (OAS) which activates RNase L to inhibit viral replication 
(Takeuchi & Akira 2010; Malmgaard 2004; Taniguchi & Takaoka 2002). 
 
EBOV infects macrophages and dendritic cells 
Macrophages and dendritic cells are primary targets of EBOV infection (Thomas W. Geisbert 
et al. 2003; Thomas W Geisbert et al. 2003). Since these cells are key players for the 
activation of the innate and adaptive immune responses their infection may implicate a 
deregulated antiviral immunity.  
Studies in vitro and in non-human primates have shown that when macrophages are 
infected with EBOV they are able to initiate strong inflammatory responses through the 
production of pro-inflammatory cytokines, chemokines and nitric oxide. This leads to the 
attraction of more macrophages and monocytes as well as neutrophils to the site of 
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infection, exacerbating the inflammatory response and the pathogenic manifestations of the 
disease (Gupta et al. 2001; Hensley et al. 2002; Mohamadzadeh et al. 2006; Bray & Geisbert 
2005; Zampieri et al. 2007; Caballero et al. 2016). In NHP it was observed that these infected 
cells also express high levels of tissue factor on their surface, a factor which could contribute 
to the coagulopathies (Thomas W. Geisbert et al. 2003).  
Contrary to what is observed in macrophages and monocytes, EBOV infected monocyte-
derived dendritic cells have been shown to fail to produce pro-inflammatory cytokines thus 
presenting an impaired activation of the innate immune response. Infected dendritic cells 
are also unable to undergo complete maturation and do not upregulate the expression of 
major histocompatibility complex (MHC) and co-stimulatory molecules reducing their 
capacity to prime naive T cells and activate the adaptive immune response (Yen et al. 2014; 
Bosio et al. 2003; Mahanty, Hutchinson, et al. 2003). 
There is significant evidence showing the production of high levels of pro-inflammatory 
cytokines, pro-inflammatory chemokines and anti-inflammatory cytokines during fatal EVD, 
evidencing that EBOV infection leads to the dysregulation of the host immune response 
(Hutchinson & Rollin 2007; Gupta et al. 2012; Wauquier, Becquart, et al. 2010; Baize et al. 
2002; Villinger et al. 1999). In these cases the lack of control of viral replication and spread 
probably leads to the continuous stimulation of the immune response and to 
immunopathology. There is limited evidence from EVD survivors that show an early and 
strong proinflammatory response facilitating the activation of an adaptive immune response 
(Baize et al. 2002). Moreover, studies done in asymptomatic human cases of EBOV infection 
show that they mount an early and strong pro-inflammatory response followed by a 
regulatory anti-inflammatory response and the clearance of virus infected cells through 
cytotoxic mechanisms (Leroy et al. 2000; Leroy et al. 2001). A study done on patients 
affected by the 2000-2001 SUDV outbreak in Uganda show that fatal EVD was associated 
with elevated and maintained levels of proinflammatory cytokines indicating a systemic 
inflammation (McElroy et al. 2014). 
Since dendritic cells and macrophages are early targets of infection and because of their 
migratory capacity, these cells seem to play a decisive role in the dissemination of the virus 
from the initial infection site through the lymph nodes and the blood to the affected organs 
(Thomas W Geisbert et al. 2003; Schnittler & Feldmann 1998). These data indicate a critical 
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role for macrophages and dendritic cells during EBOV pathogenesis but their relevance in in 
vivo infections still remains unclear. 
 
EBOV inhibits the IFN-I response 
EBOV is able to circumvent the host immune response and replicate freely by modulating 
the production of type I interferon (IFN-I) and the cellular responses to this cytokine. It was 
observed that EBOV infected monocyte-derived human macrophages fail to induce IFN-I by 
inhibiting the dsRNA-dependent pathway (Gupta et al. 2001). EBOV infection in endothelial 
cells inhibited the expression of antiviral genes in response to IFN (Harcourt et al. 1999). 
Experiments in mouse model have shown that poor outcome is correlated with the lack of 
activation of the IFN response (Mahanty, Gupta, et al. 2003). 
It was later found that VP35 protein inhibits IFN-I production. VP35 contributes to the 
virulence of EBOV by preventing the virus- or double-stranded RNA-mediated transcriptional 
activation of both the beta IFN (IFN-β) promoter and the IFN-stimulated ISG54 promoter. 
VP35 prevents the activation of interferon regulatory factor 3 (IRF-3), a cellular transcription 
factor relevant for the initiation of the host cell IFN response, by blocking its virus-induced 
phosphorylation, dimerization and nuclear transportation. VP35 also inhibits the antiviral 
effect mediated by double stranded RNA-dependent PKR (Basler et al. 2000; Basler et al. 
2003; Feng et al. 2007). 
VP24 protein inhibits IFN-I signaling: nuclear accumulation of tyrosine-phosphorylated STAT1 
(PY-STAT1) is blocked by VP24 specifically interacting with karyopherin α1, the nuclear 
localization signal receptor for PY-STAT1, thus inhibiting IFN-induced gene expression and 
rendering the infected cells insensitive to this antiviral response (Reid et al. 2006). 
 
Adaptive antiviral immune response 
Consecutive to the initiation of the innate immune response during viral infection is the 
activation of a virus-specific adaptive immune response. This happens through the activation 
of two indispensable reactions: inflammation and activation of dendritic cells.  
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During inflammation the activation of neutrophils and macrophages lead to the secretion of 
cytokines and chemokines. The role of cytokines is to modify the cellular environment to 
enhance the migration of cells into the tissue while chemokines attract more neutrophils 
and monocytes increasing the magnitude of the response. 
Dendritic cell maturation also associates the innate and adaptive immune responses. 
Immature dendritic cells at the site of infection are able to uptake antigens. Upon 
maturation they lose this capacity and they migrate to the lymph nodes where they become 
excel at stimulating T cell responses. Typical mechanisms that produce dendritic cell 
maturation are the recognition of products of viral pathogens by PRRs or the presence of 
proinflammatory cytokines such as tumor necrosis factor α (TNFα) and interleukin (IL)-1β 
which promote NF-κB activation (Mellman & Steinman 2001). Activated dendritic cells 
increase the expression of major histocompatibility complex (MHC) on their surface together 
with several co-stimulatory molecules such as CD80 and CD86. These cells then migrate 
while carrying the antigen from the infection site to the tissue-draining lymph nodes where 
they encounter the naïve T lymphocytes. Naïve T cells can then recognize and bind a specific 
peptide-MHC complex. The simultaneous co-stimulatory signal given by the dendritic cell 
stimulates the T cell proliferation and differentiation during a process called priming. 
 
The immunological synapse 
A critical step in the activation of the adaptive immune response is the interaction between 
peptide-MHC complex on the surface of dendritic cells and the T cell receptor on the surface 
of T cells. This process is called the immunological synapse and has two essential 
protagonists: the MHC and the T cell receptor. A second co-stimulatory signal is 
indispensable and given through the binding of the B7 molecules (CD80 and CD86) expressed 
on the surface of dendritic cells to their receptor on the surface of the T cell, CD28.  
The MHC molecules, called human leucocyte antigen (HLA) molecules in humans, are 
glycoproteins that bind peptide fragments derived from pathogens such as bacteria and 
viruses to display them on the cell surface of dendritic cells for recognition by cognate T 
cells. There are two different classes of HLA molecules, known as HLA class I and HLA class II, 
each containing several genes located mainly on chromosome 6. HLA-A, -B and –C are the 
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main class I genes while HLA-DR, -DP and –DQ are HLA class II genes. There are hundreds of 
allele variants of these genes within the human population making it likely that most 
individuals are heterozygous for these loci. Importantly, the expression of HLA alleles is co-
dominant which means that all gene products are expressed and able to present peptides. 
The allelic variation is restricted to the peptide-binding domain determining the peptide-
binding properties of the HLA molecules. The high polygenism and polymorphism that 
contribute to the diversity of HLA molecules is therefore important for the successful 
presentation of a broader array of pathogen-derived peptides and to generate a polyclonal T 
cell response to a particular antigen. 
HLA class I molecules bind short peptides derived from cytosolic pathogens which will be 
recognized by CD8 T cells while HLA class II molecules bind longer peptides from internalized 
pathogens, generated in endocytic vesicles, which will be recognized by CD4 T cells (Figure 4 
I-V). Only when bound to HLA molecules, T cell receptors on the surface of T cells are able to 
recognize antigens. CD4 and CD8 act as co-receptors binding to invariant sites on the 
peptide-HLA complex and enhancing the signal for T cell activation. 
The T cell receptor complex (TCR) consists of two different polypeptide chains termed TCR α 
and β. Each chain has a variable (V) region and a constant (C) region being the juxtaposition 
of the two V regions the antigen-binding site. Within this site there are hypervariable regions 
termed complementarity-determining regions (CDRs) because of their capacity to determine 
a surface complementary to specific antigens. CDR1, CDR2 and CDR3 have been described, 
the latest being the most variable part of the domain. The high diversity of TCRs is due to the 
rearrangement of gene segments during T cell development in the thymus. The CDR3 is 
formed in the α chain of the TCR by recombination of noncontiguous variable (V) and joining 
(J) gene segments. In the case of the β chain there is an additional diversity (D) gene 
segment.  
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Figure 4. Dendritic cells present antigens to T cells. Peptides derived from virus that infect dendritic 
cells are presented by HLA class I to CD8 T cells (I+V). In parallel, peptides derived from internalized 
viral particles are presented by HLA class II to CD4 T cells (II+IV). These peptides can also be cross-
presented on HLA class I molecules (III). CD4 T cells that recognize an HLA class II-peptide complex 
through the TCR activate the DCs by interaction of the ligand CD40L with its receptor CD40 (IV). This 
activation is translated in the upregulation of co-stimulatory molecules CD80/86 on the surface of 
DCs which interact with CD28 on CD8 T cells (V). This interaction together with the recognition of HLA 
class I-peptide complexes by the TCR lead to the differentiation of CD8 T cells into effector T cells 
(VI). These effector T cells are able to recognize HLA class I-peptide complexes on the surface of 
virally infected cells, triggering the release of cytokines and cytotoxic granules (VII). (Huber et al. 
2014) 
 
T cell response 
The cellular immune response is led by T cells. Typically, when dendritic cells and T cells 
interact via the immunological synapse, T cells undergo activation. This activation leads to 
the expression of CD40 ligand (CD40L) on the surface of T cells which binds CD40 on the 
surface of APCs promoting the upregulation of co-stimulatory molecules CD80 and CD86 and 
the stimulation of T cells through binding of these to CD28 (Figure 4 IV). Upon activation T 
cells produce several cytokines including IL-2, which will promote T cell proliferation and 
differentiation into effector T cells. Effector cells no longer require co-stimulation to act and 
become specialized as helper CD4 or cytotoxic CD8 T cells. 
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Early during the immune response CD4 T cells differentiate into several lineages of helper T 
cells with particular functions. T helper (Th) 1 and Th2 cells were first described and have 
roles in cell mediated or humoral immunity, respectively. Acute viral infections tend to 
promote the differentiation into Th1 cells and produce IL-2, INF-γ and TNF-β (Abbas et al. 
1996; Oxenius et al. 1998). Another potential fate of CD4 T cells is to become regulatory T 
cells (Tregs) which play a role in modulating the effector functions to maintain immune 
tolerance (Sakaguchi et al. 2008; Belkaid & Rouse 2005). Additionally, T follicular helper (Tfh) 
cells mediate the formation and differentiation of memory B cells (King et al. 2008; King & 
Mohrs 2009; Crotty 2011).  
Cytotoxic T cells (CTLs) can be activated directly via antigen presenting cell (APC) stimulation 
or with additional help from effector CD4 T cells that potentiate the co-stimulatory activity 
of APCs. CTLs recognize and kill virus-infected cells though several mechanisms including the 
release of cytotoxic granules containing perforins and granzymes (Peters et al. 1991). 
 
Figure 5. CTLA-4 regulates the T cell immune response. The interaction of CD28 with the co-
stimulatory molecule CD80 signals for the activation of T cells. Regulation of this activation is given 
through the interaction of CD28 with the co-inhibitory molecule CTLA-4 which leads to inhibition of 
the T cell response. The important balance between these two signals allows T cells to activate the 
cell-mediated immune response while avoiding an excessive response to cause immunopathology.  
(image from https://www.cancer.gov/about-cancer/treatment/research/first-treatment-vaccine-
approved) 
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It is important for the immune response to be regulated in order to avoid inflammation-
related immunopathology. The immune system includes T cell extrinsic and intrinsic 
regulatory mechanisms. The production of anti-inflammatory cytokines such as IL-10 by cells 
of the innate and adaptive immune system, such as dendritic cells, macrophages, 
neutrophils, T helper cells, CD8+ T cells, B cells and many more, suppresses the production of 
IFN and other proinflammatory cytokines in a T cell extrinsic way (Saraiva & O’Garra 2010; 
Couper et al. 2008). T cell intrinsic regulation of the immune response takes place when 
activated T cells express cytotoxic T-lymphocyte associated protein 4 (CTLA-4), a molecule 
that closely relates to CD28 but binds to the co-stimulatory receptors CD80 and CD86 with 
higher affinity and delivers an inhibitory signal limiting the proliferative response of T cells 
(Figure 5) (Egen et al. 2002). Similarly, programmed cell death protein 1 (PD-1) also inhibits T 
cell activation through binding its ligand PD-L1/PD-L2 and this way suppressing the TCR 
mediated signaling (Okazaki et al. 2013). A sustained expression of both these inhibitory 
markers has been associated with T cell exhaustion, a state commonly observed during 
chronic infections in which T cells are characterized with poor effector function losing their 
proliferative and cytotoxic capacities and dying (Wherry 2011). Additionally, T cell mediated 
immune suppression is regulated by Tregs. This T cell subset expresses the transcription 
factor Foxp3 which abrogates the transcription machinery for effector T cell differentiation 
converting them into Tregs. Upon infection, the balance between the activation of effector T 
and B cells and Tregs is crucial for the development of a contained but effective adaptive 
immune response. Tregs are engaged in the maintenance of immune homeostasis by 
competing with naïve T cells in interactions with APCs, hindering the activation of T cells by 
dendritic cells and through the production of immunosuppressive cytokines (Sakaguchi et al. 
2008). 
 
EBOV affects the adaptive antiviral immune response 
The effect of EBOV infection in the lymphocyte population is controversial. The impaired 
dendritic cell activation and overall immunosuppressed state during EBOV infection could 
also mean that there is poor T cell priming and proliferation. Even though EBOV does not 
replicate in these cells, during human EBOV infection there is massive lymphocyte apoptosis. 
This was deduced from the reduced percentage of T cell populations and the upregulation of 
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pro apoptotic molecules such as TRAIL or Fas-FasL (Baize et al. 1999; Gupta et al. 2007; 
Wauquier, Becquart, et al. 2010). Data collected during the last EVD outbreak in West Africa 
has allowed the analysis of the dynamics of the lymphocyte population and showed that 
there is lymphocyte proliferation preceding lymphopenia (Wolf et al. 2015; Kreuels et al. 
2014). Indeed analysis at the single cell level has shown that EVD is characterized by a 
massive T cell activation as it is indicated by the elevated co-expression of activation markers 
HLA-DR and CD38 as well as the expression of the proliferative marker Ki-67 (McElroy et al. 
2015). This study also demonstrated that the strongest T cell responses during EVD were 
mediated by CD8 T cells and directed against the viral NP, a finding highly relevant for 
vaccine design (McElroy et al. 2015).  
 
B cell response 
B cells lead the humoral response through the production of antibodies specific against viral 
particles. B cells bind, internalize and process antigen that bind specifically to their B cell 
receptor (BCR) and are activated through signals given by helper T cells which specifically 
recognize the same antigen that B cells present on their surface bound to an HLA molecule. 
Activated B cells proliferate and differentiate into plasma cells that secrete specific 
antibodies which in turn will neutralize and eliminate circulating viral particles. Initially 
plasma cells secrete IgM antibodies followed by secretion of IgG after isotype switching. 
Antibody isotype is given by the C region of the molecule and it confers a specialized 
function. IgG are specifically recognized by macrophages and neutrophils which then 
phagocyte the viral particles recognized and bound to this antibody. Following this 
mechanism neutralizing antibodies are key players for antibody mediated cytotoxicity of 
virus infected cells. 
 
B cell response during EVD 
Some controversy also exists regarding the humoral response during EVD. Early studies show 
that a defective antibody production and isotype switching was observed in EVD patients 
with poor outcome (Baize et al. 1999; Ksiazek et al. 1999). Conversely, findings in patients 
from the last EVD outbreak in West Africa indicate that survivors present an early IgM 
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response followed by IgG upregulation. Moreover, this antibody response was correlated 
with viral clearance (Kreuels et al. 2014; Wolf et al. 2015). On the other hand several studies 
show no correlation between isotype switching and viral clearance or survival (Towner et al. 
2004; Onyango et al. 2007).  
 
Immune memory 
Once the infection is cleared the T cell response contracts and most T cells undergo 
apoptosis leaving only a subset of cells that will form an antigen specific immune memory. 
These memory cells are able to respond stronger and faster upon a secondary infection 
thanks to the higher expression of adhesion and effector molecules (Ahmed & Gray 1996). 
Within this pool of memory T cells there is the distinction of effector-memory and central-
memory cells depending on their readiness to execute effector functions and proliferate. 
Effector-memory cells migrate to the sites of infection and have immediate effector 
functions while central-memory cells concentrate on lymph nodes and stimulate dendritic 
cells and differentiate into effector cells upon restimulation (Sallusto et al. 1999; Wherry & 
Ahmed 2004).  
 
Immunogenetics 
Molecules such as HLA and TCR, which have a relevant role in the interplay between innate 
and adaptive immunity, show extensive diversity which is fundamental for their function. 
The study of HLA polymorphisms has shown association of zygosity with resistance or 
susceptibility to autoimmune disease as well as with severity and outcome to infectious 
diseases. For instance, faster HIV progression has been associated with HLA homozygosity 
(Carrington 1999). This heterozygous advantage could be explained by the ability to present 
a broader range of antigenic peptides to activate a larger T cell repertoire against virus 
infected cells. On the other hand it could also be explained by a resistant adaptation of HIV 
to most common HLA alleles which are most likely to be observed in homozygous population 
(Martin & Carrington 2013). Certain HLA alleles have also been associated with protection or 
susceptibility as well as severity to HIV and HBV (Martin & Carrington 2005). In the case of 
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EBOV infection, alleles B*67 and B*15 were associated with fatal outcomes, whereas B*07 
and B*14 were associated with nonfatal outcomes highlighting the importance of HLA 
repertoire and CD8 T cell response during SUDV infection (Sanchez et al. 2007).  
The killer immunoglobulin-like receptor (KIR) is expressed on the surface of NK cells and bind 
to HLA class I signaling NK activation. Activating KIR2DS1 and KIR2DS3 genes were associated 
with fatal outcome in Ebola virus infection supporting the hypothesis that an over-activation 
of the immune response leads to the pathogenesis of EVD (Wauquier, Padilla, et al. 2010). 
The great diversity of the TCR repertoire also plays an important role during infectious 
disease. The pool of T cells is not static since activation of a particular T cell is accompanied 
by its clonal expansion. Therefore the analysis of the dynamics of the TCR repertoire can be 
important to better understand the cellular immune response. Advances in next generation 
sequencing (NGS) technologies have allowed the study of T cell clone frequencies which is 
defined by the abundance of CDR3 sequences, the region in TCRs which determines antigen 
specificity. However, there is no information about the TCR repertoire diversity during EBOV 
infection and whether there could be an association of more or less diversity with 
susceptibility or protection to the infection (Robins et al. 2009).  
It is important to detect these associations to be able to characterize protective host 
responses which could be relevant to vaccine or treatment development. 
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Aim of this thesis 
There are major unanswered questions regarding the immune response mechanisms to 
EBOV infection. Since EVD outbreaks have mostly occurred in relatively isolated places, 
clinical research on EVD has been traditionally challenging. Upon detection of the EVD 
outbreak in Guinea in March 2014 I had the chance to participate in the outbreak response 
as part of the European Mobile Laboratory (www.emlab.eu) and under the umbrella of the 
WHO. The main goal of this thesis was to study the influence of the host immune response 
to EBOV, in particular the T cell response, in patient outcome. Most of the experimental 
work was done in the field as well as the BSL4 laboratory in Hamburg.  
To achieve this goal, we sought and obtained ethics approval from the competent 
authorities in Guinea and Hamburg (permits Nº11/ CNERS/14 and PV4910) to use leftover 
blood samples generated during the diagnostic procedures in the field to perform 
immunology analyses. We established a small laboratory at Donka hospital in Conakry 
equipped with benchtop multiparametric flow cytometry. We evaluated the phenotype and 
kinetics of monocytes, neutrophils and dendritic cells as well as the physiology of the T cell 
immune response during EBOV infection in humans. Observations made on these immune 
cell populations were correlated with clinical and epidemiological data with the intention of 
identifying potential predictors of disease severity and outcome.  
This thesis had also the aim of studying the immunogenetics of EBOV infection. For this, HLA 
class I and II alleles from survivors and fatal EVD cases from the EVD outbreak in West Africa 
were determined. The potential role of HLA polymorphisms in disease outcome was then 
investigated. To estimate the strength of the T cell response in patients, we also performed 
sequencing of the TCR in survivor and fatal cases at multiple time points during the course of 
the disease.  
The final goal was to correlate all the information gathered either at the time of admission 
to the ETC or longitudinally over the course of the disease in order to have a better 
understanding of the mechanisms involved in the immune response to EBOV infection. 
Notably, this analysis could help us identify a possible mechanism that could be targeted for 
therapy or vaccine development.   
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Results 
I will present the results of my thesis in the form of two published articles and a third article 
which is in preparation. The first publication shows the results obtained regarding the role of 
antigen presenting cells during human EBOV infection. The second publication includes the 
results regarding the physiology of human T cell response during EBOV infection and the 
association of this response to disease outcome. The third article includes results on the HLA 
typing and the T cell response during human EBOV infection obtained through the 
sequencing of the T cell receptor. In the next section I will introduce each publication 
individually and present the results obtained. 
 
Publication I: Ebola Virus Disease Is Characterized by Poor Activation and Reduced Levels 
of Circulating CD16+ Monocytes (Lüdtke, Ruibal, Becker-Ziaja et al., 2016) 
Several studies have previously identified antigen presenting cells (APCs) as main targets of 
EBOV infection. It was observed in both in vitro and non-human primate studies that there is 
an important deregulation of the innate and adaptive immune response as a consequence of 
the infection of macrophages and dendritic cells with EBOV. However the role of these cell 
populations in human disease remains unknown.  
Several subsets of APCs can be found circulating in human blood including neutrophils, 
dendritic cells and monocytes. The monocyte population can be further divided in three 
subsets: classical CD14+ monocytes, non-classical CD16+ monocytes and intermediate 
CD14+CD16+ monocytes. CD14+ monocytes recognize bacteria and specialize in phagocytosis 
(Saha & Geissmann 2010). In contrast, CD16+ monocytes are especially relevant for antiviral 
immunity since they are able to recognize viral RNA and activate proinflammatory pathways 
through TLR7 and TLR8 receptors signaling (Cros et al. 2010). Dendritic cells lack both CD14 
and CD16 markers and are subdivided into CD1c+ and CD141+ populations (Collin et al. 2013). 
These two groups of dendritic cells in blood are believed to be the precursors of dendritic 
cells in both lymphoid and non-lymphoid organs (Dzionek et al. 2000). 
In this study, we looked at the alterations of APCs in the blood of 28 EBOV infected patients 
at the time they were admitted to the ETC using 34 febrile EBOV negative patients as a 
control group. Our first observation was the decrease in the amount of circulating 
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monocytes in EVD patients compared to EBOV negative patients. This reduction was 
especially remarkable for CD16+ monocytes and was also observed when patients were 
classified according to outcome with lower amounts of CD16+ monocytes in fatal cases 
compared to survivors. This reduction was observed again when the patients were grouped 
according to their cycle threshold (Ct) value, an indicator of viral load. A significant loss of 
CD16+ monocytes was correlated to a higher viral load while patients with lower viral loads 
showed similar abundances to convalescent and control patients. Additionally, a significant 
loss of CD14+ monocytes was also observed in patients with higher viral loads. 
It was shown in vitro that the infection of monocyte-derived DCs with EBOV causes an 
impaired function including lack of maturation and poor T cell stimulation (Mahanty, 
Hutchinson, et al. 2003). However, this effect has not been studied in vivo. To address this 
question, we used HLA-DR expression on the surface of the cells as an activation marker, 
apart from the cell surface markers used for identification of the different APC subsets. This 
analysis showed that EBOV infected patients with higher viral loads presented a significantly 
lower expression of HLA-DR on CD14+ and CD16+ monocytes when compared to 
convalescent and control patients, strongly suggesting an inhibition of the infected 
monocyte subsets.  
In order to analyze the phenotype and kinetics of APCs activation longitudinally we were 
able to obtain multiple samples from 5 survivors and 3 fatal cases. In survivors, we could 
observe an increase in the expression of HLA-DR during recovery. Moreover, monocyte 
activation was correlated with viral clearance. On the other hand, fatal cases presented a 
maintained low expression of HLA-DR. These data show that the activation of monocytes, in 
particular CD16+ monocytes, may be important for the host immune response against EBOV 
infection and could be relevant for viral clearance. This also indicates that this cell 
population may be an important component of EBOV induced immunosuppression. 
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Figure 1. Left: human EVD fatal cases were characterised by high viremia and a reduction in the 
number of circulating monocytes. Two possible explanations for this are the death of infected 
monocytes (1) or the extravasation of the monocytes to the sites of infection (2). The reduction in 
the number of circulating monocytes together with the low activation status of these cells leads to 
the inability of the host to eliminate the virus. Right: human EVD survivors were characterised by the 
activation of monocytes, indicated by the upregulation of HLA-DR expression (3). We hypothesize 
that this activation could contribute to the efficient priming of naive T cells (4), leading to the 
activation of the adaptive immune response and the host control of viral replication.  
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A number of previous studies have identiﬁed antigen-presenting cells (APCs) as key targets of Ebola virus (EBOV), but the role of
APCs in human Ebola virus disease (EVD) is not known. We have evaluated the phenotype and kinetics of monocytes, neutrophils,
and dendritic cells (DCs) in peripheral blood of patients for whom EVD was diagnosed by the European Mobile Laboratory in Guinea.
Acute EVD was characterized by reduced levels of circulating nonclassical CD16+ monocytes with a poor activation proﬁle. In survi-
vors, CD16+ monocytes were activated during recovery, coincident with viral clearance, suggesting an important role of this cell subset
in EVD pathophysiology.
Keywords. Ebola virus; Ebola virus disease; monocytes; CD16; CD14.
Ebola virus (EBOV) causes severe disease in humans that is par-
tially deﬁned by alterations of the host immune response. In
particular, professional antigen-presenting cells, including mac-
rophages and dendritic cells (DCs), are readily infected with
EBOV in vitro, and viral infection causes inhibition of DC ac-
tivation [1, 2]which is a necessary step for the initiation of adap-
tive antiviral immunity [3]. However, it is not known whether
EBOV infection inﬂuences APC function in vivo, and the role of
APCs on Ebola virus disease (EVD) pathophysiology remains to
be elucidated.
Several subsets of APCs or their precursors can be found in
human blood, including monocytes and DCs. Blood monocytes
can be subdivided in 3 subsets based on phenotype and func-
tion: classical CD14+ monocytes are deﬁned by their capacity
to produce proinﬂammatory cytokines and chemokines in re-
sponse to lipopolysaccharide [4]. Conversely, nonclassical
CD16+ monocytes have been proposed to have an antiviral
role [5, 6]. Indeed, CD16+ monocytes can recognize viral
RNA through their expression of Toll-like receptor 7 (TLR7)
and TLR8 [5]. Intermediate CD14+ CD16+ monocytes have
been also identiﬁed but are less well characterized functionally
[4]. Precursors of conventional CD1c+ and CD141+ DCs, as well
as plasmacytoid DCs and activated HLA-DR+ neutrophils, can
be also identiﬁed in human blood [7, 8]. The kinetics and phe-
notype of these APCs may be used to evaluate human immune
responses to pathogens and vaccines [9].
To gain insight into the function of APCs during human EVD,
we evaluated the alterations in this cell compartment in patients
with EVD at the time of admission to the Ebola treatment center
(ETC). The self-reported median time of admission after symp-
tom onset among these patients was day 4 for both survivors
and patients who died (Supplementary Figure 1). In addition,
we monitored the activation status of APCs longitudinally in 8 pa-
tients, of whom 3 died and 5 survived. Our ﬁndings indicate that
human EVD is characterized by a signiﬁcant decrease in circulat-
ing CD16+ monocytes and a poor activation of this cell subset.
Survivors showed activation of CD16+ monocytes during recov-
ery, concurrent with viral clearance. Our work shows that a reduc-
tion of the CD16+ monocyte population and poor activation of
this cell subset are important features of human EVD.
METHODS
Patients
Patients with acute EVD (ie, those who tested positive for EBOV
by reverse transcription–polymerase chain reaction [RT-PCR])
included in the study were attended at the ETC in Coyah
(n = 28), under the care of medical teams deployed by the
Cuban government. The median age of our patient cohort
was 32 years (interquartile range, 20–43 years). Patient samples
were obtained at the time of admission at the ETC, and patients
with malaria parasite coinfection were excluded from the study.
Additionally, 34 febrile EVD-negative controls were included
in the study. The National Committee of Ethics in Medical
Research of Guinea, as well as the Ethics Committee of the
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Medical Association of Hamburg, approved the use of diagnos-
tic leftover samples and corresponding patient data for this
study (permits 11/CNERS/14 and PV4910). Because the sam-
ples had been collected as part of the public health response
to contain the outbreak in Guinea, informed consent was not
obtained from patients.
Study Samples and Flow Cytometry
Real-time RT-PCR was performed on blood samples in ethyl-
enediaminetetraacetic acid (EDTA)–lined tubes that were col-
lected from patients with suspected acute EVD, using the
RealStar Zaire Ebolavirus RT-PCR Kit 1.0 (Altona Diagnostics),
at the European Mobile Laboratory (EMLab) unit in Coyah.
Malaria was diagnosed using a rapid test. Leftover samples
from diagnostic assays were shipped within 24 hours after col-
lection to our immunology laboratory at Donka Hospital in
Conakry and processed immediately. Thirty samples from con-
valescent patients, namely patients who recovered from acute
EVD and were PCR negative for EBOV, were included in the
study. Of these, 19 samples were from 12 surviving patients in-
cluded in the acute EVD cohort.
Peripheral blood mononuclear cells (PBMCs) were isolated
from whole-blood specimens in EDTA-lined tubes. Red blood
cells were lysed with Red Blood Cell Lysing buffer (BD Biosci-
ences). Immunophenotyping was achieved via a multiparamet-
ric ﬂow cytometry panel, using the following commercially
available antibodies: CD3-PerCP/Cy5.5 (SK7), CD19-PerCP/
Cy5.5 (HIB19), CD56-PerCP/Cy5.5 (HCD56), HLA-DR-PE/
Cy7 (L243), CD11c-PB (Bu15), CD14-BV510 (M5E2),
CD141-PE (M80), CD1c-APC (L161), and CD16-APC/Cy7
(3G8). All antibodies were from Biolegend. PBMCs were treated
with ﬂuorescence-activated cell-sorting block (Human TruStain
Fc receptor blocking antibodies from Biolegend) for 20 minutes
followed by staining with antibodies. After staining, samples
were inactivated in Cytoﬁx/Cytoperm (BD) buffer in the pres-
ence of 4% formaldehyde. Sample acquisition was done in
a Guava easyCyte 8 ﬂow cytometer from Millipore. Analysis
of ﬂow cytometry data was done with FlowJo software
(Treestar).
Statistical Analysis
Nonparametric statistics was performed in GraphPad Prism
software, using the Kruskal–Wallis test and the Dunn multiple
comparison test. Sample distributions are illustrated via box
plots. Boxes extend from the 25th to 75th percentiles, and the
horizontal bar is plotted as the median. The bars (whiskers) rep-
resent the sample distribution down to the 10th percentile
(lower bar) and up to the 90th percentile (upper bar).
RESULTS
To evaluate the phenotype of APCs in the peripheral blood of
patients with EVD at the time of admission to the ETC, we used
ﬂow cytometry to identify classical CD14+ and intermediate
CD14+CD16+ monocytes, nonclassical CD16+ monocytes, acti-
vated HLA-DR+ neutrophils, and DCs (Figure 1A). We ﬁrst
compared the concentrations of these cell subsets in peripheral
blood of patients with EVD and febrile patients who tested neg-
ative for EVD. We observed a reduction in the levels of all cir-
culating monocyte subsets and CD1c+ DCs in patients with
EVD, compared with febrile controls, with a very signiﬁcant de-
crease in CD16+ monocytes (Figure 1B and Supplementary Fig-
ure 2). When patients with acute EVD were classiﬁed on the
basis of outcome, the number of circulating CD16+ monocytes
was also signiﬁcantly lower in patients who died, compared with
survivors (Figure 1B). We did not ﬁnd any signiﬁcant differenc-
es between the groups with regard to the circulating levels of
neutrophils, other DC subsets, or total peripheral blood mono-
nuclear cells. To determine whether our ﬁndings indicated spe-
ciﬁc reduction of particular immune subsets, rather than a
generalized loss of APCs, we also determined the percentages
of monocytes and DCs within the APC gate. These analyses
also indicated that monocytes and CD1c+ DCs were reduced
among the blood APCs, with a very signiﬁcant reduction of
CD16+ monocytes in patients who died of EVD (Supplementa-
ry Figures 2 and 3).
To gain insight into the relevance of these ﬁndings for the
pathophysiology of human EVD, we sought to determine the
correlation between the levels of circulating monocytes and,
as a readout of the viral load, the cycle threshold (Ct) value.
Our results indicated that the concentration of CD14+ and
CD16+ monocytes in blood samples from patients with EVD
was positively correlated with the Ct value, which indicated
that reduced numbers of these cells in peripheral blood was cor-
related with high viremia levels (Figure 2A). These results sug-
gested that EVD is marked by a decrease in circulating
monocytes and that this phenotype was exacerbated in patients
with high viral loads, a known predictor of poor outcome [10].
To further explore the relationship between reduced levels of
monocytes and EVD severity, we determined the concentration
of these cells in all diagnostic EVD samples for which Ct values
were available. Samples were classiﬁed into 3 groups: those with
Ct values of < 25, 25–33, or > 33. A fourth group was formed by
samples from convalescent patients with EBOV-negative PCR
results, and, ﬁnally, another group was formed by samples
from EVD-negative febrile patients. The samples from patients
with a high viremia level (Ct value, < 25) showed signiﬁcantly
reduced levels of CD16+ monocytes, compared with samples
from patients with a low viremia level (Ct value, > 33), samples
from PCR-negative convalescent patients, and samples from
other acute febrile patients (Figure 2B). We also observed signif-
icantly reduced levels of CD14+ monocytes and intermediate
monocytes in samples with a Ct value of < 25 as compared to
those from convalescent patients, further suggesting that, dur-
ing EVD, a generalized decrease in peripheral blood monocytes
occurs. In addition to circulating monocytes, the concentration
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of conventional CD1c+ DCs was reduced in samples from pa-
tients with high-level viremia, compared with those from febrile
controls (Supplementary Figure 2).
EBOV infection of monocyte-derived DCs results in inhibi-
tion of DC activation, mainly because of the ability of viral pro-
tein 24 (VP24) and VP35 to antagonize the type I interferon
pathway [11, 12]. However, to the best of our knowledge,
EBOV-derived effects on APC activation have never been dem-
onstrated in vivo. Previous studies have indicated that low levels
of expression of major histocompatibility complex class II
(HLA-DR) molecules in monocytes and other APCs is associ-
ated with reduced activation and loss of antigen presentation
capacity [13, 14]. Thus, to determine the activation status of
APCs in patients with EVD, we measured the expression levels
Figure 1. Analysis of antigen-presenting cells (APCs) in peripheral blood of patients with Ebola virus disease (EVD). A, Gating strategy for flow cytometric analysis of APCs in
peripheral blood. APCs were gated as follows: G1, APCs; G2, CD14+ monocytes (MOs); G3, CD14+CD16+ MOs; G4, CD14− APCs; G5, HLA-DR+ neutrophils; G6, CD14−, SSClow
cells; G7, CD16+ MOs; G8, DC gate; G9, CD1c+ DCs; and G10, CD141+ DCs. B, Box plots depicting the concentrations of CD14+ monocytes, HLA-DR+ neutrophils, CD16+
monocytes, CD14+CD16+ monocytes, and total peripheral blood mononuclear cells (total cells). Graphs indicate comparison between acute EVD cases (red) with febrile controls
(gray), as well as between individuals who died (green) and those who survived (turquoise). “Other” denotes febrile EVD-negative controls. All patient samples were obtained at
admission to the Ebola treatment center. *P≤ .05 and ****P≤ .0001, by the Kruskal–Wallis test and the Dunn multiple comparison test. Abbreviation: ns, not significant.
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Figure 2. Relationship between antigen-presenting cell (APC) concentrations, activation status, and Ebola virus disease (EVD) severity. A, Graphs showing the correlation
between the concentrations of CD16+ and CD14+ monocytes and the cycle threshold (Ct) values in 57 samples that tested positive for EVD at the European Mobile Laboratory
(EMLab) unit in Coyah, Guinea. Lines represent linear regression. B, Box plots showing the concentrations of CD16+ monocytes, CD14+ monocytes, CD14+ CD16+ monocytes, and
HLA-DR+ neutrophils in patient samples. The samples were grouped according to their Ct values. Three groups were distinguished for patients with EVD: Ct < 25 (red), Ct = 25–33
(green), and Ct > 33 (turquoise). The fourth group comprised convalescent patients with Ebola virus (EBOV)–negative polymerase chain reaction results (white), and the fifth
group comprised patients with other undiagnosed febrile illnesses (gray). C, Box plots representing HLA-DR expression on CD14+ and CD16+ monocytes grouped as in panel B.
HLA-DR expression was assessed by calculation of the median fluorescence intensity (MFI) of this molecule on the cell surface. D, Longitudinal analysis of HLA-DR expression
of CD14+ and CD16+ monocytes (left axis) and Ct values (right axis; reversed) for patients who died of EVD (F1–3) and those who survived EVD (S1–5). Correlation analysis was
done using the nonparametric Spearman correlation test. *P≤ .05, **P≤ .01, ***P≤ .001, and ****P≤ .0001, by the Kruskal–Wallis test and the Dunn multiple comparison
test. Abbreviation: ns, not significant.
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of HLA-DR in CD14+ and CD16+ monocytes in diagnostic
samples stratiﬁed according to the Ct values. All acute PCR-
positive samples showed signiﬁcant reduced expression of
HLA-DR in both monocyte subsets, compared not only with
samples from convalescent patients, but also with samples
from febrile controls (Figure 2C). These data strongly suggested
that inhibition of monocyte activation is a prominent feature of
EVD.
To explore the kinetics of monocyte subsets during EVD re-
covery, we studied the activation status of monocytes over time
in 8 patients with EVD for whom longitudinal samples were
available. Three of these patients died (F1–F3), and 5 survived
(S1–S5). While all 3 fatal cases displayed low levels of expression
of HLA-DR in both monocyte compartments, all surviving pa-
tients had increased expression of HLA-DR over the course of
disease, in particular in the CD16+ subset, which coincided with
viral clearance (Figure 2D). Taken together, our results suggested
that a signiﬁcant reduction in the levels of circulating monocytes
is correlated with EVD severity and that robust activation of
CD16+ monocytes is associated with survival.
DISCUSSION
The main conclusion to be drawn from our data is that human
EVD is characterized by a decrease in circulating monocytes
and a poor activation proﬁle of these blood cells. Both the re-
duced levels of blood monocytes and their low activation was
correlated with high viremia levels. The reduced levels of circu-
lating cells was especially signiﬁcant in nonclassical CD16+
monocytes, even compared with ﬁndings for other acutely fe-
brile patients. In addition, the levels of blood CD16+ monocytes
were signiﬁcantly reduced in patients who died of EVD, com-
pared with those in survivors, suggesting a putative association
between CD16+ monocyte function and EVD outcome. Con-
versely, survivors of EVD showed robust activation of this cell
subset during recovery, which coincided with viral clearance.
These ﬁndings suggested that loss of CD16+ monocyte function
is an important component of EVD pathophysiology.
It is conceivable that monocytes may be directly infected by
EBOV, which could explain why these cells are lost in samples
from patients with high viremia levels. We failed to demonstrate
direct infection or apoptosis of APC subsets in ﬁeld conditions,
and, thus, further research is necessary to address this hypothesis.
An important function of CD16+ monocytes is to patrol the
endothelium and to extravasate to peripheral inﬂammation
sites, where they can differentiate into macrophages and DCs
[5]. Thus, another explanation for the loss of these cells in pe-
ripheral blood of patients with high-level viremia could be mas-
sive extravasation to infection sites. In this scenario, it would be
highly relevant to determine whether CD16+ monocytes could
be acting as so-called viral vessels favoring systemic virus dis-
semination. A previous study has indicated that EBOV may
attach to the surface of monocytes preferentially infecting these
cells during their differentiation into DCs or macrophages [15].
It is also plausible that CD16+ monocytes play a more active
role in the EBOV-speciﬁc antiviral response. In fact, these cells
have been shown to respond poorly to bacterial cues but to be
able to sense viruses through TLR7/8, leading to production of
speciﬁc antiviral cytokines [5]. Our ﬁnding that surviving
patients with EVD were able to upregulate expression of
HLA-DR in CD16+ monocytes over time suggests activation
and possible involvement in viral clearance.
In summary, our study indicates that the levels and functional
status of monocytes and in particular nonclassical CD16+ mono-
cytes in peripheral blood of patients with EVD is an important
component of EVD pathophysiology and suggests that this cell
subset may play a key role in host immunity against EBOV.
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Publication II: Unique human immune signature of Ebola virus disease in Guinea (Ruibal, 
Oestereich, Lüdtke, Becker-Ziaja et al., 2016) 
Conflicting observations have been made regarding the T cell response to EBOV infection in 
humans and animal models. Early studies in EBOV infected patients indicated an important 
lymphocyte apoptosis during fatal EVD probably as a result from excessive T cell activation 
combined with the inability to control viral replication (Baize et al. 1999). Later in vitro 
experiments led to the conclusion that EBOV infection of human PBMCs caused massive T 
cell apoptosis, which was proposed as a possible cause for the delay in the production of 
antibodies (Gupta et al. 2007). The death of T cells during the immune response to EBOV 
infection could possibly be explained by the lack of effective priming by virus-infected DCs. 
However data from two patients infected during the last EVD outbreak in West Africa and 
who were airlifted to two different hospitals in Germany indicated lymphocyte proliferation 
preceding lymphopenia (Kreuels et al. 2014; Wolf et al. 2015). Moreover, the use of flow 
cytometry allowed the analysis at the single cell level of a small number of EVD patients 
treated at Emory University Hospital and showed a strong T cell activation over the course of 
EVD as seen by the upregulation of T cell activation markers such as  HLA-DR and CD38 
(McElroy et al. 2015).  
The conclusions made on T cell activation and proliferation during EVD, were drawn from 
observations in a limited number of patients treated with intensive supportive treatment as 
well as experimental therapy. On the contrary, studies that lead to the observation of 
lymphocyte apoptosis and immunosuppression during EVD were done in vitro or on patients 
with little access to health care. It’s important to take into account these aspects and it is 
also necessary for larger studies to be done in order to have a better representation of the 
human disease.  
All these studies have shown that even though the T cell population is not directly infected 
by EBOV, the dynamic of their response is clearly affected by the infection and could have 
important consequences to disease outcome. Although a robust T cell activation is observed 
during EVD this does not always lead to viral clearance. This ineffective T cell response could 
be related to defects in the regulation of T cell immune function. CTLA-4 and PD-1 are 
receptors that negatively regulate T cell activation and are essential for autoimmune control 
but their sustained expression could lead to T cell exhaustion, a state characterized by the 
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loss of effector function (Wherry 2011). With this in mind, we obtained a large number of 
peripheral blood samples from EVD patients and evaluated the activation status of T cells. 
We focused our analysis in the comparison of survivors and fatal cases in early time points of 
the disease as well as longitudinally until recovery or death. 
A large number of leftover blood samples from EVD patients diagnosed by the EMLab in 
Guéckédou were sent to our BSL4 laboratory in Hamburg. For this study we initially included 
47 EBOV positive patients and 61 EBOV negative patients as control and we performed flow 
cytometry analysis to investigate the functional status of T cells during EVD. The analysis 
showed that there was an upregulation in the expression of the inhibitory marker CTLA-4 in 
both CD4 and CD8 T cells of EBOV infected patients compared to EBOV negative patients. 
However, the quality of these samples was questionable since they were stored and 
transported for days before we could analyze them.  
In order to ensure a better quality of the samples we set up an immunology lab where we 
could receive the samples shortly after diagnosis at the ETC in Coyah. As mentioned 
previously, we received daily leftover diagnosis samples at Donka Hospital in Conakry. In 
these samples, we observed an upregulation in the expression of CTLA-4 in both CD4 and 
CD8 T cells of EBOV infected patients compared to non-infected patients, confirming our 
previous results. Moreover, when EBOV positive samples were grouped according to 
outcome, we observed that at the time of admission to the ETC the upregulation of CTLA-4 
as well as PD-1 were correlated with fatal outcome. HLA-DR, an activation marker, and Ki-67, 
a proliferation marker, were also upregulated in CD4 and CD8 T cells respectively, in fatal 
cases compared to survivors. Levels of plasma cytokines were measured with multiplex ELISA 
in the BSL4 laboratory in Hamburg. The results showed higher levels of pro-inflammatory 
cytokines such as TNFα and IL-8, and chemokines such as macrophage inflammatory protein 
(MIP)-1α, MIP-1β and monocyte chemotactic protein (MCP)-1, in fatal cases compared to 
survivors. Moreover, levels of anti-inflammatory cytokines such as IL-10 were also higher in 
fatal cases suggesting the activation of compensatory mechanisms which is consistent with 
the expression of CTLA-4 and PD-1. 
While we were in the laboratory in Donka Hospital in Conakry we received more samples 
than we were able to process and analyze, so part of the samples were carefully stored and 
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transported to our BSL4 laboratory in Hamburg. We decided to analyze these samples in 
order to apply a more complex flow cytometry panel that would allow us to look into the co-
expression of CD38 and HLA-DR as well as CD38 and Ki-67 to define activated T cells. We also 
observed the co-expression of CTLA-4 and PD-1 to characterize effector T cells that had 
activated inhibitory mechanisms. Our results show a strong T cell activation in both fatal 
cases and survivors. Once again, the co-expression levels of CTLA-4 and PD-1 were 
upregulated in CD4 and CD8 T cells from fatal cases compared to those of survivors, 
supporting once more our previous results. We could observe that CD4 and CD8 T cells 
upregulating CTLA-4 expression were also expressing high levels of HLA-DR and CD38 
suggesting that these were activated T cells with an effector function that have started 
regulatory mechanisms. 
The cycle threshold (Ct) value is an indicator of viral load and a strong predictor of outcome 
(Lanini et al. 2015). In agreement with this, we observed that Ct values at the time of 
admission were significantly lower in fatal cases compared to survivors. When comparing Ct 
values with the co-expression levels of CTLA-4 and PD-1 also at the time of admission we 
observed a negative correlation. Altogether, low Ct value and high levels of co-expression of 
CTLA-4 and PD-1 could be used as predictors of bad outcome.  
In order to investigate whether the observations we had done corresponded to EBOV-
specific responses, we designed MHC-I dextramers that would allow us to track EBOV-
specific T cells. For this, we selected HLA class I alleles commonly expressed in the West-
African population such as HLA-A*02:01, HLA-A*23:01 and HLA-B*35:01 and chose EBOV-NP 
derived peptides that bind these alleles with high affinity, since it was shown that NP drives 
most of the CD8 T cell responses (Modiano et al. 2001; Sundar et al. 2007; Simmons et al. 
2004). With this technology we could detect the development of an EBOV-specific T cell 
population over time. Even though both fatal cases and survivors showed similar levels of 
EBOV-specific T cells detected at the time of admission only survivors were able to mount an 
EBOV-specific T cell response which was correlated with viral clearance and recovery.  
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Figure 2. Left: human EVD fatal cases were characterised by a dysregulation of the adaptive immune 
response indicated by the upregulation of the inhibitory markers CTLA-4 and PD-1 on the surface of 
both CD4 and CD8 T cells, and the increased expression of the anti-inflammatory cytokine IL-10. 
These observations were correlated with high levels of viremia. Right: human EVD survivors were 
characterised by the development of EBOV-specific T cell responses accompanied by the clearance of 
the virus and recovery from the disease.  
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Despite the magnitude of the Ebola virus disease (EVD) outbreak 
in West Africa, there is still a fundamental lack of knowledge 
about the pathophysiology of EVD1. In particular, very little is 
known about human immune responses to Ebola virus2,3. Here 
we evaluate the physiology of the human T cell immune response 
in EVD patients at the time of admission to the Ebola Treatment 
Center in Guinea, and longitudinally until discharge or death. 
Through the use of multiparametric flow cytometry established 
by the European Mobile Laboratory in the field, we identify an 
immune signature that is unique in EVD fatalities. Fatal EVD 
was characterized by a high percentage of CD4+ and CD8+ T cells 
expressing the inhibitory molecules CTLA-4 and PD-1, which 
correlated with elevated inflammatory markers and high virus 
load. Conversely, surviving individuals showed significantly lower 
expression of CTLA-4 and PD-1 as well as lower inflammation, 
despite comparable overall T cell activation. Concomitant with 
virus clearance, survivors mounted a robust Ebola-virus-specific 
T cell response. Our findings suggest that dysregulation of the T cell 
response is a key component of EVD pathophysiology.
During the initial months of the EVD outbreak in Guinea, we trans-
ferred leftover blood samples from EVD patients diagnosed by the 
EMLab in Guéckédou (n = 47) to Europe (Extended Data Fig. 1a and 1b). 
Immunophenotyping analysis of these samples, indicated a sig-
nificantly higher expression of CTLA-4 in CD8+ T cells from EVD 
patients compared to non-EVD patients (n = 61) (Extended Data 
Fig. 1c). The levels of CTLA-4 were significantly higher in CD8+  
T cells from fatal EVD cases compared to survivors (Extended Data 
Fig. 1d). CTLA-4 plays an important role in inhibiting T cell func-
tion, an immune homeostasis mechanism to control excessive or per-
sistent T cell activation4,5. Owing to its regulatory properties, there 
are licensed therapeutics to either antagonize or enforce CTLA-4 
function6,7. Thus, we hypothesized that our findings could reflect a 
pathophysiological mechanism of EVD that might be amenable to 
therapeutics. However, we had concerns regarding the quality of the 
material that arrived at our laboratory after days of transport and we 
therefore established flow cytometry directly in Guinea to further eval-
uate T cell immunity in EVD. Leftover diagnostic blood samples from 
157 EVD patients tested by the EMLab at the Coyah Ebola Treatment 
Center (ETC) were transferred to our laboratory in Conakry within 
24 h after collection (Extended Data Fig. 2a, b). The median day of 
admission at the ETC for both fatalities and survivors was day 4 post 
symptom onset and, thus, outcome was not associated with the time 
elapsed between onset of disease and admission (Fig. 1a).
First, we evaluated the immune status of EVD patients upon their 
arrival to the ETC. Owing to the limitation to six parameters in our 
field analyses (Extended Data Fig. 3), we focused on the evaluation 
of individual markers of T cell function. We determined the expres-
sion levels of HLA-DR and Ki-67 as markers of activated T cells8, as 
well as PD-1 and CTLA-4, which together are key regulators of T cell 
homeostasis5,9. The percentage of CD4+ and CD8+ T cells expressing 
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CTLA-4 and PD-1 was significantly higher in fatal cases compared 
with survivors (Fig. 1b). Sometimes more than 50% of total CD8+ 
T cells expressed CTLA-4 (Fig. 1c). Fatal cases also showed higher 
frequency of Ki-67+ CD8+ T cells and HLA-DR+ CD4+ T cells than 
survivors (Fig. 1b).
High expression of both PD-1 and CTLA-4 has been correlated with 
functional exhaustion (loss of function) of T cells in chronic inflam-
matory conditions9–11. However, the role of these molecules during 
acute infection is less well understood. In previous studies, expres-
sion of CTLA-4 and PD-1 in T cells correlated with the extent of pro- 
inflammatory responses against hantavirus and influenza virus 
among others12–14. Thus, we next evaluated the levels of pro- and anti- 
inflammatory cytokines in fatal and non-fatal EVD. In agreement with 
previous reports15,16, fatal EVD cases had significantly higher levels of 
serum pro-inflammatory cytokines (TNF (also known as TNFα) and 
IL-8) (Fig. 1d). Moreover, the levels of pro-inflammatory chemo kines 
(MIP-1α, MIP-1β and MCP1) were also significantly upregulated in 
fatalities (Fig. 1d). Levels of anti-inflammatory cytokines such as IL-10 
were also higher in fatalities suggesting the onset of compensatory 
homeostatic mechanisms in response to excessive inflammation, 
consistent with expression of T cell inhibitory molecules such as 
CTLA-4 and PD-1.
To gain insight into the correlation between CTLA-4 expression and 
the functional status of T cells in patients we performed analyses of 
T cells from cryopreserved peripheral blood leukocytes, which allowed 
evaluation of T cell marker co-expression (Extended Data Fig. 4). We 
used co-expression of CD38 and HLA-DR as well as CD38 and Ki-67 
to define activated T cells3,8,13, and co-expression of CTLA-4 and PD-1 
to identify effector T cells that had activated inhibitory mechanisms13. 
Our results indicated robust CD8+ T cell activation in both fatal and 
non-fatal EVD cases with no statistically significant difference between 
the two groups. The frequency of activated CD8+ T cells (around 30% 
of CD38+ HLA-DR+ and 18% of CD38+ Ki-67+) was similar to that 
previously reported in acute surviving medevac EVD patients3, and 
to that described in other acute infections13 and after vaccination8. 
However, the frequency of CD8+ T cells co-expressing PD-1 and 
CTLA-4 was significantly higher in fatalities (Fig. 2a, b). The results 
with CD4+ T cells corresponded to those of CD8+ T cells, with no 
differences in the activation status between fatal and non-fatal EVD, 
but a higher frequency of cells co-expressed CTLA-4 and PD-1 in fatal 
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Figure 1 | Immune signature of EVD at the 
time of admission. a, Day of symptom onset at 
admission. b, Frequencies of CD8+ T cells (left) 
and CD4+ T cells (right) positive for the indicated 
markers. Black boxes represent fatal cases and 
blue boxes represent survivors. c, Plots of four 
survivors and four fatalities showing frequencies 
of CTLA-4+ CD8+ T cells. d, Levels of plasma 
cytokines in fatal versus surviving EVD cases. 
Statistical analysis was performed by Mann–
Whitney test: NS, not significant; *P ≤ 0.05; 
**P ≤ 0.01; ***P ≤ 0.001.
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cases (Fig. 2c, d). CTLA-4+ T cells in both CD8+ and CD4+ subsets 
expressed high levels of CD38 and HLA-DR, suggesting a discrete sub-
set of effector T cells that have initiated a compensatory homeostatic 
mechanism (Fig. 2b, d).
Whether or not CTLA-4 overexpression affects T cell-mediated 
viral clearance is controversial. While some reports have correlated 
the frequency of CD8+ T cells expressing CTLA-4 with poor viral 
clearance14, others do not support this hypothesis17. To explore the 
relationship between CTLA-4 and PD-1 expression and virus loads 
during EVD, we analysed whether the percentage of T cells express-
ing CTLA-4, PD-1, or both, correlated with the threshold cycle (Ct) 
values of the EBOV real-time PCR. Fatal EVD cases had signifi-
cantly lower Ct values at the time of admission in agreement with the 
Ct value being a strong predictor of outcome18–20 (Extended Data 
Fig. 2c–e). The Ct value negatively correlated with the percentage 
of T cells expressing CTLA-4 as well as the percentage of CD8+ T 
cells co-expressing CTLA-4 and PD-1 (Fig. 2e and Extended Data 
Fig. 5a). However, the percentage of T cells expressing PD-1 alone 
did not correlate with the Ct value (Fig. 2f). In summary, expression 
of CTLA-4 alone and in combination with PD-1 correlated with high 
viraemia.
Acute lymphopenia triggers proliferation of naive T cells with very 
low expression of CTLA-4 and PD-1 (ref. 21). Thus, we reasoned that 
differences in Ebola virus (EBOV)-induced lymphopenia2, could be a 
confounding variable in our study. However, there were no differences 
in circulating peripheral blood T cells between fatal and non-fatal EVD 
cases (Extended Data Fig. 5b). A recent study comparing infection 
with the Makona versus Mayinga variants of EBOV in non-human 
primates found evidence of initial leukocytosis followed by moder-
ate lymphopenia with no overall differences between both EBOV 
variants22. Initial leukocytosis in patients infected with the Makona 
variant of EBOV has been also observed23,24, which indicates the need 
of longitudinal evaluation of haematological parameters in patients 
infected with EBOV Makona, an approach that was not possible in 
our study due to the lack of statistically relevant numbers of fatal cases 
with longitudinal sampling.
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Figure 2 | Functional properties of T cells in 
EVD patients. a, Frequencies of CD8+ T cells  
co-expressing the indicated markers. b, Plots 
of two surviving and two fatal EVD patients 
depicting CD8+ T cell populations co-expressing  
the indicated markers. Overlays indicate activation 
status of CTLA-4+ CD8+ T cells (red). Total  
CD8+ T cells are represented by black contours.  
c, CD4+ T cells co-expressing the indicated 
markers. d, Plots of two surviving and two fatal  
patients depicting CD4+ T cell populations  
co-expressing the indicated markers. Overlays  
indicate activation status of CTLA-4+ CD4+  
T cells (red). Total CD4+ T cells are represented by 
black contours. e, Correlation between frequency 
of CD8+ T cells (upper graph) and CD4+ T cells 
(lower graph) expressing CTLA-4 and Ct values. 
f, Correlation between the frequency of CD8+ 
T cells (upper graph) and CD4+ T cells (lower 
graph) positive for PD-1 and Ct values. Statistic 
analysis was performed by Mann–Whitney test: 
NS, not significant; *P ≤ 0.05; **P ≤ 0.01.
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To link the observed activation of CD8+ T cells with EBOV-specific 
responses, we sought to track EBOV-specific CD8+ T cells during 
infection through the use of HLA class I dextramers. We first per-
formed in silico analysis of EBOV nucleoprotein-derived peptides 
predicted to bind with high affinity to selected HLA alleles common 
in West Africa (HLA-A*02:01, HLA-A*23:01 and HLA-B*35:01)25 
and designed dextramers (Extended Data Fig. 6). We chose the EBOV 
nucleoprotein based on previous reports indicating that nucleoprotein 
drives most of the CD8+ T cell response26,27. Dextramer-matching 
HLA alleles were identified in 26 patients via sequencing of the HLA 
locus. Six patients had more than one sample for longitudinal evalua-
tion of EBOV-specific T cell responses. These included two fatal cases 
(F1 and F2) and four survivors (S2–S5). S3 and S4 were treated with 
favipiravir, and all the other patients received only supportive therapy. 
At the time of admission, the differences in the percentage of EBOV-
specific T cells between fatalities and survivors were not statistically 
significant (Fig. 3a). However, differences became evident during later 
stages of infection. The fatal cases with longitudinal sampling (F1 and 
F2) showed a high frequency of PD-1+ CTLA-4+ CD8+ T cells until 
death, but barely detectable EBOV-specific CD8+ T cells (Fig. 3b, e). In 
contrast, an increase in the frequency of EBOV-specific CD8+ T cells 
was observed in survivors in coincidence with virus clearance and 
decrease of the PD-1+ CTLA-4+ CD8+ T cell population (Fig. 3c–e).
These findings were substantiated by the kinetics of CTLA-4 
expression in two EVD patients, one fatality and one survivor, evac-
uated to Europe, as well as five survivors treated in Coyah, Guinea. 
Longitudinal analysis of these patients revealed persistent upregula-
tion of CTLA-4 in the fatal case and transient upregulation in survi-
vors (Extended Data Fig. 7). Of note, the increase of EBOV-specific 
T cells in the surviving patients coincided with contraction rather than 
expansion of the CD38+ HLA-DR+ subset (Fig. 3e). Despite the fact 
that the phenotype of activated T cells (CD38+ HLA-DR+) suggests 
engagement of the T cell receptor (TCR) and not bystander T cell 
activation8, our findings may point to the presence of non-EBOV- 
specific T cells within the CD38+ HLA-DR+ compartment.
The main hypothesis we formulate on the basis of these data is that 
differences between the T cell response of fatal and surviving EVD 
patients are centred in the mechanisms that regulate T cell home-
ostasis. While all patients showed T cell activation irrespective of 
outcome, it was the expression of the regulatory molecules CTLA-4 
and PD-1 on peripheral blood T cells that marked fatal EVD and cor-
related with high viraemia, a known predictor of poor outcome19,20. 
We hypothesize that this upregulation reflects a compensatory mech-
anism to excess inflammatory stimuli, which is consistent with the 
concomitant expression of pro-inflammatory cytokines in fatal cases. 
However, our findings do not indicate causality between expression 
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Figure 3 | Longitudinal evaluation of EBOV-
specific T cell immunity. a, Frequency of EBOV-
specific CD8+ T cells in EVD patients at admission. 
Statistic analysis was performed by Mann–Whitney 
test: NS, not significant. b, Frequency of CD8+ 
T cells specific for the HLA-A*02:01-restricted 
peptide FLSFASLFL. Two fatal patients (F1 and 
F2, see panel d) are shown and day of sample 
evaluation post onset is indicated in parentheses. 
A surviving patient (S1) and fatal patient (F3) 
are shown for positive HLA-A*02:01 dextramer 
staining. c, Frequencies of CD8+ T cells specific for 
the HLA-B*35:01-restricted FPQLSAIAL peptide 
are shown in survivors (S3, S4 and S5) with serial 
sampling. d, Plots of one survivor (S2) showing 
staining of EBOV-specific CD8+ T cells restricted 
for HLA-A*23:01 AYQGDYKLF. e, Longitudinal 
patient data at the indicated days after symptom 
onset. Left axis represents the frequency of CD8+ 
T cells co-expressing CD38 and HLA-DR (black), 
CTLA-4 and PD-1 (red) and dextramer-positive 
cells (blue). Dextramer background was assessed 
in HLA-matched healthy donors (Extended Data 
Fig. 6b), and background dextramer staining is 
shown as dashed blue lines. The corresponding flow 
cytometry plots are shown in panels a–d. Ct values 
are represented for each patient with dashed lines 
and values depicted in the right axis.
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of CTLA-4/PD-1 and poor outcome: on one hand it is possible that 
high viraemia triggers overwhelming inflammation thereby causing 
CTLA-4 and PD-1 upregulation on T cells, and on the other hand, 
it is plausible to assume that expression of these molecules inhibits 
T cell function leading to poor viral clearance. Indeed, both possi-
bilities have been reported in the literature13,28 and their elucidation 
requires evaluation of CTLA-4 function during EVD in adequate 
infection models. Interestingly, during severe EVD, both PD-1 and 
CTLA-4 are upregulated while in other acute human infections such as 
hantavirus disease and paediatric influenza, only CTLA-4, not PD-1, 
was upregulated13,14. These results suggest that different infections 
trigger specific regulatory mechanisms, the balance of which is vital 
for optimal T cell function. Robust T cell activation was observed in 
both fatal and non-fatal EVD cases as reflected by similar levels of 
discrete CD8+ and CD4+ T cells co-expressing CD38 and HLA-DR. 
These results are in agreement with the strong T cell activation 
observed in surviving US patients3 and strengthen the notion that 
EVD is characterized by immune activation. Although limited, our 
dextramer data suggest that both fatal and non-fatal cases are able to 
mount EBOV-specific T cell responses. However, while in survivors 
the PD-1+ CTLA-4+ CD8+ T cell compartment contracted in con-
junction with viral clearance, formation of EBOV-specific T cells and 
recovery, this did not seem to be the case in fatal EVD. One plausible 
explanation for this finding is that the high expression of CTLA-4 
observed in activated T cells of fatal cases promotes cell extrinsic inhi-
bition of EBOV-specific T cells. T-cell-extrinsic CTLA-4 functions 
have been demonstrated in vivo and involve different mechanisms 
such as stripping of T cell co-stimulatory molecules from antigen- 
presenting cells, stimulation of regulatory T cells and local tryptophan 
starvation among others5,29,30. Further functional experiments with 
adequate in vivo models are needed to explore the role of regulatory 
T cell molecules during EVD and to test whether their modulation 
may serve as a putative post-exposure therapy against EVD.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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METHODS
No statistical methods were used to predetermine sample size. The experiments 
were not randomized and the investigators were not blinded to allocation during 
experiments and outcome assessment.
Patients. EVD patients included in the study were managed at the Ebola 
Treatment Centers in Guéckédou (n = 47) and Coyah (n = 157) under the med-
ical care of Médecins sans Frontières and doctors deployed by the Cuban gov-
ernment, respectively. Patients with malaria co-infection were excluded from the 
study. Two patients evacuated into Europe for medical treatment were included 
in the study for longitudinal analysis. One patient was treated at the University 
Medical Center Hamburg-Eppendorf, Hamburg, Germany, and the other one at 
the Hospital La Paz, Madrid, Spain. Demographic and outcome data for EVD 
patients were obtained from databases of the World Health Organization. The 
National Committee of Ethics in Medical Research of Guinea as well as the Ethics 
Committee of the Medical Association of Hamburg approved the use of diagnostic 
leftover samples and corresponding patient data for this study (permits Nº11/
CNERS/14 and PV4910). This study was also approved by the protocol review 
office of the US National Cancer Institute institutional review board. As the sam-
ples had been collected as part of the public health response to contain the outbreak 
in Guinea, informed consent was not obtained from patients. Informed consent 
was obtained from the two EVD patients treated in Hamburg and Madrid.
Study samples and flow cytometry analysis. Real-time RT–PCR was performed 
on EDTA-blood of patients with suspected EVD using the RealStar Ebolavirus 
RT–PCR Kit 1.0 (Altona Diagnostics) at the European Mobile Laboratory (EMLab) 
units in Guéckédou and Coyah. Malaria was diagnosed using a rapid test. Whole 
blood samples from Guéckédou were shipped to the biosafety level 4 (BSL-4) lab-
oratory in Hamburg within 1–3 weeks after collection and processed immediately 
upon arrival via multiparametric flow cytometry.
Leftover samples from Coyah were shipped within 24 h after collection to the 
EMLab immunology laboratory at Donka Hospital in Conakry. PBMCs were iso-
lated after sedimentation of cells in EDTA whole blood tubes. Red blood cells were 
lysed with Red Blood Cell Lysing buffer (BD Biosciences). PBMCs were processed 
immediately upon reception for immunophenotypic analysis or were cryopre-
served and transported to the BSL-4 laboratory in Hamburg. Immune pheno-
typing was achieved via multiparametric flow cytometry panel using a battery 
of commercially available antibodies as follows: anti-human (h) CD3-APCCy7 
(clone UCHT1), anti-hCD4-FITC (clone OKT4), anti-hCD8-PeCy7 (clone 
RPAT8), anti-hCD152 (CTLA-4)-PE (clone L3D10), anti-hCD279 (PD-1)-APC 
(clone EH12-2HT), anti-hHLA-DR-PerCP Cy5.5 (clone L243), anti-hKi67-PE 
(clone 16A8), anti-hCD38-APC (clone HB-7). All antibodies were from Biolegend. 
Single-cell PBMC suspensions were incubated with live/dead discrimination dye 
(Zombie-NIR from Biolegend) followed by FACS block (Human TruStain Fc 
receptor blocking antibodies from Biolegend) for 20 min followed by staining 
with antibodies against extracellular antigens. After extracellular staining samples 
were inactivated in Cytofix/Cytoperm (BD) buffer in the presence of 4% formal-
dehyde followed by staining with intracellular antibodies (anti-CD3, Ki-67 and 
CTLA-4). Sample acquisition was done in a Guava easyCyte 8 Flow Cytometer 
from Millipore in Guinea. In Hamburg, samples were thawed at 37 °C and the 
sample volume transferred to ice-cold 15-ml falcon tubes where 5 ml ice-cold R8 
medium (RPMI + 8% FBS) were added. Sample tubes were then centrifuged to 
remove the cryopreservant (10% DMSO) at 1,000 r.p.m. for 10 min and resus-
pended in R8 medium. Samples were centrifuged once more and the pelleted 
cells were washed with 12 ml of ice-cold R8 medium. Samples were processed 
as indicated above. In experiments involving dextramer staining, samples 
were incubated in a volume of 50 μl of PBS with 5 μl of the indicate dextramers 
(1:10 dilution) before extracellular antibody staining. All dextramers were pur-
chased from Immudex. Samples were acquired in a LSR Fortessa instrument (BD). 
Flow cytometry analysis was done with FlowJO software (Treestar).
In silico peptide analysis. Prediction of EBOV nucleoprotein-derived peptide 
binding to selected human HLA alleles was achieved using an artificial neural 
network method at the Immune Epitope Database and Analysis Resource (IEDB) 
(http://www.iedb.org). Selected peptides (IC50 < 50 nM) were then cross-checked 
with two additional matrix-prediction algorithms, BIMAS (http://www-bimas.
cit.nih.gov) and SYFPEITHI (http://www.syfpeithi.de). Peptides predicted by all 
three bioinformatic tools were selected and screened for similarity to the human 
genome using the NIH Blast server. Peptides showing homology to the human 
proteome were discarded.
Multiplex ELISA. Concentrations of selected cytokines and chemokines were 
measured in 1:2 diluted plasma samples using Milliplex Map Human Cytokine/
Chemokine Magnetic Bead Panel (EMD Millipore, Missouri, USA) on the 
Luminex platform LX200 (Luminex, Austin, USA). The procedure was performed 
according to the manufacturer’s instructions.
HLA genotyping. High-resolution genotyping for HLA class I loci was performed 
by PCR-sequence-based typing, as recommended by the 13th International 
Histocompatibility Workshop (available at: http://www.ihwg.org). HLA sequences 
were analysed using the ASSIGN software (Conexio Genomics).
Statistical analysis. Non-parametric statistics and plots were performed in 
Graphpad Prism software as described in the figure legends. Sample distribution 
is illustrated throughout the manuscript using box-and-whisker plots. In all figures 
the boxes extend from the 25th to 75th percentiles and the horizontal bar is plotted 
as the median. The bars (whiskers) represent sample distribution down to the 10th 
percentile (lower bar) and up to the 90th percentile (upper bar).
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Extended Data Figure 1 | Initial immunophenotyping data from 
Guéckédou. a, Graph depicting the number of samples tested by the 
EMLab unit in Guéckédou by function of time since the beginning of the 
outbreak. The blue square indicates the period in which leftover whole 
blood samples from the diagnostic activities were shipped to the BSL-4 
laboratory in Hamburg for initial immunophenotyping. b, Demographic 
data of the Guéckédou EVD patient cohort. Adults were ≥ 18 years of 
age and paediatric patients were <18 years of age. c, Comparison of the 
expression of CTLA-4 assessed by median fluorescence intensity ratio 
(MFIR) in CD4+ and CD8+ T cells of EVD patients (POS, black boxes) 
and non-EVD controls (NEG, green boxes). MFIR represents the ratio 
between the CTLA-4-specific signal divided by the fluorescence minus 
one (FMO) signal of the same cell population. d, Comparison between 
CTLA-4 MFIR values in CD8+ T cells from fatal (black) versus surviving 
(blue) EVD cases. In all panels, the ends of the whiskers in the box-and- 
whisker plots represent the 10th and 90th percentile, respectively. 
Statistical analysis was performed by non-parametric Mann–Whitney test; 
*P ≤ 0.05; ***P ≤ 0.0001.
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Extended Data Figure 2 | Epidemiological data of patients tested by 
EMLab unit in Coyah. a, b, Demographic data of the Coyah EVD patient 
cohort. Adults were ≤18 years of age and paediatric patients were  
<18 years of age. The median age of the 157 patients in the study was  
26 years (interquartile range (IQR) 20–38 years). Percentages of males  
and females were comparable within all groups, with adults accounting  
for 79% of patients. c, Box-and-whisker plots depicting statistical 
association between Ct values and outcome. The case–fatality ratio (CFR) 
was 51.6%. Fatalities and survivors were compared via non-parametric 
Mann–Whitney test; ***P < 0.001. d, Correlation between Ct value and  
age of the patients. The Ct value did not correlate with age. However, 
survivors clustered in a group characterized by Ct value higher than  
18 and by age less than 40 years (cluster encircled in blue). Statistical 
significance was tested by non-parametric Spearman correlation analysis. 
e, Ct values correlated negatively with symptom scoring, so that low  
Ct values were associated with severe disease symptoms. Symptom score 
was calculated as the summation of individual symptoms (bleeding, liver 
dysfunction, respiratory distress, kidney failure, neurological symptoms 
and anorexia) from ‘0’ (no symptoms) to ‘6’ (all symptoms present).  
In the box-and-whisker plot the ends of the whiskers represent the 10th 
and 90th percentile, respectively. Statistical analysis was performed by 
non-parametric Mann–Whitney test; ***P ≤ 0.0001.
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Extended Data Figure 3 | Gating strategy for flow cytometry studies in 
Guinea. All samples evaluated in the field were aliquoted for four panels. 
All panels had the following common gating: G1, lymphocyte gate; G2,  
live cells; G3, singlets; G4, T cells; G5, CD4+ T cells; G6, CD8+ T cells. 
Panels 1, 2, 3 and 4 evaluated expression of HLA-DR, Ki-67, CTLA-4 and 
PD-1, respectively, in either CD4+ or CD8+ T cells.
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Extended Data Figure 4 | Gating strategy for flow cytometry in 
Hamburg. Cryopreserved PBMC samples from Coyah were thawed 
as indicated in the Methods. The following gates were used for sample 
analysis: G1, lymphocyte gate; G2, live cells; G3, singlets; G4, T cells;  
G5, CD4+ T cells; G6, CD8+ T cells. In G5 or G6, samples were evaluated 
for co-expression of the indicated cell markers. Dextramer staining was 
evaluated in G6 following protocols described in the Methods.
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Extended Data Figure 5 | Correlation of double positive PD-1+/CTLA-4+  
CD8+ T cells with Ct values and lymphopenia. a, Graph showing 
correlation between the frequency of CD8+ T cells co-expressing PD-1 
and CTLA-4 and the Ct value. Correlation analysis was done via  
non-parametric Spearman correlation test. b, Box-and-whisker plots 
depicting the concentration of CD4+ and CD8+ T cells in blood of fatal 
and surviving EVD patients. The ends of the whiskers in the box-and-
whisker plots represent the 10th and 90th percentile, respectively.
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Extended Data Figure 6 | In silico peptide analysis and dextramer 
design. a, Selection of peptides consisting of nine amino acid residues 
corresponding to the EBOV nucleoprotein sequence predicted to bind 
the indicated HLA alleles. IC50 values for peptide binding to HLA were 
predicted by the artificial neural network (ANN) at the Immune Epitope 
Database and Analysis Resource (IEDB) (http://www.iedb.org).  
b, Dextramer background was determined by staining of HLA-matched 
healthy donor peripheral blood leukocyte samples. T cells were gated 
as indicated in Extended Data Fig. 4. Plots in the upper row represent 
staining of a FMO (fluorescent minus one) sample in which the APC 
channel was left empty. Lower rows show background dextramer staining 
as indicated. The mean background staining plus minus standard 
deviation is indicated for each dextramer and the FMO.
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LETTERRESEARCH
Extended Data Figure 7 | Longitudinal analysis of CTLA-4 expression 
in the CD8+ T cell compartment during the course of EVD in two 
patients. a, Graph depicts the levels of expression of CTLA-4 in CD8+  
T cells of a fatal versus a surviving EVD case over the course of the disease. 
Both patients were treated in Europe. Samples were taken at consecutive 
days starting immediately after patient admission as indicated. MFIR 
represents the ratio between the CTLA-4-specific signal divided by  
the fluorescence minus one (FMO) signal of the same cell population.  
b, Longitudinal analysis of CTLA-4 expression in CD8+ T cells and  
Ct values in survivors from Coyah.
© 2016 Macmillan Publishers Limited. All rights reserved
61 
 
Publication III: Immunogenetics of Ebola virus disease (manuscript in preparation) 
Our results on the phenotype and functional status of antigen presenting cells and T cells 
during EBOV infection strongly suggested that the functional status of these cells is altered 
during infection and highly dysregulated in fatal EVD cases. Therefore, we sought to further 
investigate the interface between dendritic cells and T cells by examining the role of HLA 
polymorphisms and the T cell receptor (TCR) on EVD outcome. One previous study 
conducted in the context of Sudan virus in a limited number of patients, associated the 
alleles B*67 and B*15 with fatal outcomes, whereas B*07 and B*14 were associated with 
nonfatal outcomes (Sanchez et al. 2007).  
Thus, we isolated genomic DNA from 352 patients and had them typed through a 
collaboration with Prof. Mary Carrington (National Institutes of Health, USA). We were able 
to obtain the HLA class I allele information from 123 survivors and 107 fatal cases and the 
HLA class II allele information from 111 survivors and 101 fatal cases. When we analyzed the 
possible association of zygosity with disease outcome we observed a significant association 
of HLA class I, in particular HLA-A allele homozygosity with fatal cases. None of the other HLA 
class I or class II showed any association with outcome. This implies that there is 
heterozygous advantage to EVD which could be interpreted as an ability to present a 
broader range of viral antigens which results in a more diverse T cell response. A similar 
observation has been made in the case of HIV and HBV infections (Martin & Carrington 2013; 
Carrington 1999; Thio et al. 1999). However when looking at specific allele frequencies in 
both populations we did not observe any significant differences that indicated association of 
any of the individual alleles with disease outcome. 
Our findings suggested that an ability to respond to a broader range of EBOV epitopes could 
provide an advantage to the host. Therefore, we next investigated the association between 
T-cell repertoires and disease outcome. 
In order to shed some light on the importance of the T cell receptor in the immune response 
to EBOV infection we sequenced the complementarity determining region 3 (CDR3) of the 
TCR- β chain using genomic DNA isolated from the patients. We focused on the CDR3 region 
of the β chain because it is the one that shows the highest variability. CDR3 sequences can 
be translated into T cell clones since each T cell clone has a unique and distinct CDR3 
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sequence. By looking into the diversity of CDR3 sequences in the patient’s blood we were 
able to infer how broad the T cell response was and we correlated this to disease severity 
and outcome. In total we collected information on TCR diversity from 22 fatal cases and 18 
survivors. Our results showed that survivors developed a more diverse T cell response when 
compared to fatal cases, which was in agreement with the beneficial effect of heterozygous 
HLA in EVD survival. Moreover, when we observed the distribution of shared clonotypes 
among fatal cases and survivors we could observe that survivors express mainly private TCR 
sequences while the TCR repertoire from fatal cases is more widely shared. 
We additionally investigated the expansion of the T cell response over time by examining the 
TCR diversity, as readout of T cell clonal expansion, at different time points after infection in 
5 fatal cases and 5 survivors. Our data indicated that the highest diversity observed in 
surviving individuals was also correlated with a more rapid T cell expansion and a decrease in 
the viral load. Conversely, clonal T cell expansion was delayed in fatal cases and was not 
associated with the control of viral replication. 
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Immunogenetics of EVD 
Abstract 
The HLA class I and II genes play a very important role in the initiation of the adaptive 
immune responses. These molecules are highly polymorphic in order to present a wide array 
of antigenic peptides and different levels of this diversity as well as the expression of specific 
alleles have been associated to improved immune responses to viral infections. Facing the 
HLA-peptide complex during the immunological synapse, the CDR3 sequence in the T cell 
receptor (TCR) determines antigen specificity of the T cell responses. In order to be able to 
recognize the infinite possibility of peptides presented, the TCR display a highly diverse 
repertoire which can also be correlated to an improved capacity of the host to clear viral 
infections. In this study we genotyped the HLA class I and II alleles from fatal cases and 
survivors in order to evaluate the potential influence of these alleles expression in disease 
outcome. We also sequenced the TCR of Ebola virus disease (EVD) patients who succumbed 
or survived the disease and evaluated the possible influence of the TCR repertoire diversity 
in the clearance of Ebola virus (EBOV) and in recovery. Our findings support the importance 
of HLA and TCR polymorphisms for the activation of a broad and effective adaptive immune 
response. 
 
Introduction 
Ebola virus disease (EVD) is a severe disease caused by infection with Ebolavirus that affects 
humans and non-human primates, with reported case-fatality rates as high as 90% in 
humans. EVD outbreaks usually occur in African countries with the last one affecting mainly 
West African countries such as Guinea, Sierra Leone, Liberia and Nigeria. The West African 
outbreak was caused by Zaire ebolavirus (EBOV) and had an unprecedented magnitude with 
over 28000 infected people and caused over 11000 deaths (World Health Organization 
2016).  
It has been established that EVD is characterized by alterations in the host immune 
response. EBOV primary target of infection are antigen presenting cells (APCs). Upon 
infection in vitro, monocyte-derived dendritic cells (DCs) present an impaired activation 
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being unable to mature and efficiently prime naïve T cells in order to activate the adaptive 
antiviral immune response (Bosio et al. 2003; Mahanty, Hutchinson, et al. 2003). We have 
observed in EVD human patients that CD14+ and CD16+ monocytes found in peripheral blood 
are reduced in number. Moreover, a decrease in monocytes activation was associated with 
high viral load (Lüdtke et al. 2016). Additionally, an altered functional status was also 
observed on T cells of EVD patients. Robust activation of T cells, indicated by high co-
expression levels of CD38 and HLA-DR, was observed in EVD patients but with no correlation 
to viral clearance or disease outcome. Flow cytometry analysis showed a significantly higher 
co-expression of the inhibitory markers CTLA-4 and PD-1 in fatal cases compared to 
survivors. This upregulation was also correlated with higher viral loads (Ruibal et al. 2016). 
These results imply that EVD is defined by alterations of the host immune response as an 
important part of its pathophysiology. 
Some immune response genes which are highly relevant for the interplay between innate 
and adaptive immunity such as the HLA class I and II genes of the major histocompatibility 
complex (MHC) show extensive diversity. Some allele variants have been shown to correlate 
with susceptibility or resistance to infectious disease such as HIV or HBV (Martin & 
Carrington 2005). The effect of HLA diversity on viral disease could be explained by the fact 
that individuals who are heterozygous for the HLA alleles have a capacity to present a higher 
diversity of pathogen-derived peptides and thus to activate a more diverse T cell response, 
hence increasing the ability of the immune system to respond to a broader array of 
pathogens. This mechanism of heterozygous advantage has already been described in the 
context of HIV infection where HLA-I heterozygosity is associated with a slower disease 
progression (Carrington 1999; Tang et al. 2004). Specific HLA alleles have also been 
associated with protection or susceptibility as well as severity to HIV and HBV (Martin & 
Carrington 2005). In the case of EBOV infection, alleles B*67 and B*15 were associated with 
fatal outcomes, whereas B*07 and B*14 were associated with nonfatal outcomes 
highlighting the importance of HLA repertoire and CD8 T cell response during EBOV infection 
(Sanchez et al. 2007).  
Another important molecule in the activation of adaptive immune responses is the T cell 
receptor (TCR) which also presents a wide diversity in order to be able to recognize a broad 
spectrum of antigenic peptides. Following this theory, it has been suggested that TCR 
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repertoire diversity is correlated with an enhanced viral control in the context of HIV and 
HCV infections (Meyer-Olson et al. 2004; Lopes et al. 2003).  
In this study we analyzed the potential impact of HLA class I and II alleles polymorphism and 
TCR diversity in the severity and outcome to EVD. We obtained information on allele 
expression of the HLA class I from 123 survivors and 107 fatal cases as well as on the HLA 
class II from 111 survivors and 101 fatal cases. In addition, we obtained the TCR sequence 
from 22 fatal cases and 18 survivors at an early time point of the disease as well as 
longitudinally for 5 fatal cases and 5 survivors. Our findings suggest an heterozygote 
advantage in EVD but no specific HLA alleles could be linked to outcome. An increased TCR 
diversity was associated with viral clearance and survival to EVD. We observed an expression 
of more unique TCR sequences among survivors, while fatal cases showed an expression of a 
more public repertoire suggesting a possible association between the diversity of the T cell 
response in the population and the capacity of the virus to escape the immune response. 
Altogether, our results support the need to identify EBOV peptides that are able to elicit a 
highly diverse TCR repertoire for the development of efficient vaccines. 
 
Methods 
Patients and samples. All samples were obtained from EVD patients that were diagnosed at 
the Ebola Treatment Centers (ETC) in Guéckédou or Coyah. Diagnosis for EBOV was done on 
blood samples in EDTA tubes using the RealStar Zaire Ebolavirus RT-PCR Kit 1.0 (Altona 
Diagnostics) by the European Mobile Laboratory (EMLab). A fraction of leftover diagnosis 
whole blood was frozen and shipped to the BSL4 laboratory in Hamburg.  
Genomic DNA isolation. Genomic DNA was isolated from whole blood using TRIzol Reagent 
and according to the manufacturer’s instructions. Briefly, approximately 70 μl of whole 
blood was homogenized in 1 ml of TRIzol reagent. Homogenized samples were stored at -
80°C. For extraction, samples were thawed and incubated at room temperature (RT) for 5 
minutes. 0,2 ml of chloroform was added to the samples which were then shaken and 
incubated for 3 minutes at RT. The samples were then centrifuged at 10600 rpm for 15 
minutes at 4°C during which the mixture separates into two phases. The upper aqueous 
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phase was discarded and DNA was precipitated from the lower phenol-chloroform phase by 
adding 0,3 ml of 100% ethanol to the phenol-chloroform phase. The mix was incubated for 3 
minutes at RT and then centrifuged at 4400 rpm for 5 minutes at 4°C. The phenol-ethanol 
supernatant was transferred to a new tube for protein isolation. The DNA pellet was then 
washed twice with 1 ml of 0,1 M sodium citrate in 10% ethanol incubated for 30 minutes at 
RT. The sample was then centrifuged at 4400 rpm for 5 minutes at 4°C and the DNA pellet 
was resuspended in 1,5 ml of 75% ethanol. After 15 minutes incubation at RT the sample 
was centrifuged again, the supernatant was discarded and the DNA pellet was air dried for 
10 minutes before resuspension in 50 μl 8mM NaOH. DNA samples were stored at -20°C. 
HLA genotyping. High-resolution genotyping for HLA class I loci was performed by PCR-
sequence-based typing, as recommended by the 13th International Histocompatibility 
Workshop (available at: http://www.ihwg.org). HLA sequences were analysed using the 
ASSIGN software (Conexio Genomics). 
TCR amplification. TCR sequences were obtained by amplifying the TCR β CDR3 loci from 
samples of genomic DNA. The TCR library was generated with the use of Multiplex PCR using 
45 forward primers each specific to a functional TCR Vβ segment and 13 reverse primers 
each specific to a TCR Jβ segment (Robins et al. 2009). Forward and reverse primers were 
pooled separately to a final stock of 10 μM each. Multiplex PCR amplification was performed 
in a first step with the use of a 1:5 mix of primers without and with overhang adapters. The 
Qiagen multiplex PCR kit was used in a final volume of 25 μl including 1 μl of DNA template 
and 2,5 μl of Q solution. The PCR cycle was initiated by a 15 minutes step of activation of the 
HotStartTaq DNA Polymerase at 95°C. Next, denaturation at 94°C for 30 seconds was 
followed by annealing for 90 seconds at 69°C, with touchdown PCR of 1°C reduction of the 
temperature for the first 10 cycles. After extension at 72°C for 90 seconds, 40 cycles (10 
cycles for touchdown + 30 cycles) of denaturation, annealing, and extension followed. A final 
extension at 72°C was performed for 10 minutes. A second PCR step was performed to 
include Nextera XT dual indices as well as Illumina sequencing adapters. The Qiagen 
multiplex PCR was used once again in a final volume of 25 μl including 5 μl of DNA template 
and 2,5 μl of each primer. The PCR cycle was initiated with an activation step of 15 minutes 
at 95°C followed by 15 cycles of denaturation for 30 seconds at 95°C, annealing for 30 
seconds at 55°C and extension for 30 seconds at 72°C. A final extension at 72°C was 
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performed for 5 minutes. PCR products were purified after each PCR run with the use of 
Agencourt AMPure XP reagent. PCR products were mixed with 1,8x volume of beads for the 
recovery of amplicons of about 200bp. 
Sequencing. For the sequencing of the TCR amplicons the Illumina MiSeq chemistry V3 was 
used and a paired end 300 cycle run was performed following the manufacturer’s 
instructions. The pooled and denatured library was diluted to a final concentration of 12 pM 
and a a PhiX control of 5% spike-in was used. 
Bioinformatical analysis of sequencing results. For the comprehensive analysis of the large 
amount of reads obtained from the sequencing of TCR the use of bioinformatic tools was 
necessary. First, sequence reads were evaluated for their quality with the use of PRINSEQ-
lite and PRINSEQ-graphs (v0.20.4) (Schmieder & Edwards 2011). Next, paired sequence reads 
were interleaved and filtered for their quality with the use of the sequence processing 
utilities “interleave_pairs” and “filter_by_quality” found in seq_crumbs 
(https://bioinf.comav.upv.es/seq_crumbs/). Read pairs were required to have a minimum 
quality score of 25. Those read pairs that met this requirement were merged over their 
overlapping sequences in order to obtain complete sequences of our target region with the 
use of FLASH (v1.2.9) (Magoč & Salzberg 2011). MiXCR (v1.8.1) was used to align the 
obtained sequences to reference V, D and J genes of T cell receptors in order to identify the 
genes present in the samples. Then, identical CDR3 sequences are identified and grouped in 
clonotypes. All this information can finally be exported into a tab-delimited and 
understandable text file (Bolotin et al. 2015). Afterwards, the R package tcR was used for 
advanced data analysis on the files obtained from MiXCR (Nazarov et al. 2015). tcR allowed 
the comparison of TCR repertoire among several samples and the calculation of the inverse 
simpson index as an indicator of diversity. 
Statistical analysis. Associations between HLA-allele expression and outcome were assessed 
using Chi-square test with Bonferroni correction for multiple tests. Associations between 
TCR diversity and outcome, Ct value and others were determined using Mann-Whitney test.  
The levels of significance are interpreted as follows: NS (not significant) p>0,05, *p≤0,05, 
**p≤0,01, ***p≤0,001, and ****p≤0,0001. 
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Results 
HLA effects on EVD. To evaluate the potential impact of HLA polymorphism in EVD severity 
and outcome we genotyped the HLA class I alleles from 123 survivors and 107 fatal cases as 
well as on the HLA class II alleles from 111 survivors and 101 fatal cases. We first evaluated 
the effect of HLA zygosity in EVD severity by calculating the percentage of survivors and 
fatalities that were heterozygotes for each HLA locus. With the use of a Chi-square test we 
found an association between the frequency of heterozygosity in the HLA-A locus and 
disease outcome (Figure 1). We observed a significantly higher frequency of heterozygotes 
among the survivors when compared to fatalities. This heterozygous advantage could be 
interpreted as an enhanced capacity for the presentation of a broader array of antigenic-
peptides activating this way a larger repertoire of T cells.  
 
Figure 1. HLA gene zygosity in EVD patients. This graph represents the frequency at which HLA allele 
heterozygosity is found in survivors or fatal cases of EVD. Associations between heterozygosity and 
outcome were assessed with Chi-square test showing a significant association between 
heterozygosity of HLA-A and survival. 
To further investigate the role of HLA polymorphism in EVD severity we calculated the 
frequencies of each HLA allele expressed in both fatal cases and survivors. For the 
calculation of allele frequencies in fatal cases and survivors a simple count of alleles was 
done. If there are two alleles at each locus, H and h, then there are three possible 
combinations for these: one heterozygote (Hh or hH) and two homozygotes (HH and hh). In 
the case of the HLA loci, since there are multiple possible alleles the frequency of each is 
calculated by counting its presence or absence. For example, to obtain the frequency of HLA-
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A*02 at locus HLA-A, A2 would be the presence of HLA-A*02 and X would be the presence of 
any allele except HLA-A*02 (Table 1).  
Table 1. Distribution of the HLA-A*02 allele in fatal cases of EVD. 
Genotype A2:A2 A2:X X:X 
Observed individuals 6 31 86 
Amounts of allele A2 12 31 0 
Amounts of allele X 0 31 172 
 
Since this count is done in 123 patients, there are 246 alleles at the HLA-A locus and the 
allele frequency of HLA-A*02 is calculated as (12+31)/246=0,17 and the frequency sum of all 
the alleles except HLA-A*02 is (31+172)/246=0,83, being the sum of both frequencies 1. Only 
alleles for which a minimal frequency of 2% was observed were taken into account for 
association analyses. We used a Chi-square test with Bonferroni correction to look at 
possible associations between HLA allele expression and disease outcome (Figure 2). No 
significant associations could be detected for any of the HLA loci.  
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Figure 2. HLA allele frequencies in EVD patients. HLA classes I (A) and II (B) allele frequencies in 
survivors and fatal cases of EVD. Only alleles with frequencies equal or superior to 2% are 
represented. Chi-square test with Bonferroni correction for multiple tests showed no significant 
differences in the expression of alleles when comparing survivors and fatal cases. 
 
TCR diversity in the immune response to EBOV infection. To explore the possible role of 
TCR diversity in the immune response to EBOV infection and its association with EVD 
outcome we amplified and sequenced the TCRβ CDR3 region from 22 EVD fatal cases and 18 
survivors at early time points of the disease. The inverse Simpson diversity index, a value 
that provides a measurement of the degree of diversity within a dataset by taking into 
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account the frequency of each clonotype, was calculated with the use of the R package 
called tcR (Venturi et al. 2007). We then used the Mann Whitney test for the analysis of 
correlation between the TCR diversity and outcome. Our first observation was that the TCR 
diversity was significantly higher in survivors in comparison to fatal cases, in consistence 
with our results regarding the heterozygous advantage for the HLA-A locus (Figure 3A). To 
ensure that no bias was being introduced with regard to the time after onset of symptoms at 
which the samples had been obtained we confirmed that this value is not different among 
the two different groups (Figure 3B). We could also confirm, as it was observed in previous 
studies, that the cycle threshold (Ct) value, an indicator of viral load, is significantly higher in 
survivors compared to fatalities meaning that a high viral load is an indicator of poor disease 
outcome (Figure 3C). When correlating Ct value and TCR diversity we observed that there is 
a positive correlation between the two values indicating that a higher TCR diversity is 
associated with lower viral load (Figure 3D). 
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Figure 3. TCR diversity in survivors and fatal cases of EVD. The inverse Simpson index is represented 
here as an indicator of TCR diversity. Values were obtained for 22 fatal EVD cases and 18 EVD 
survivors. Associations between disease outcome and TCR diversity (A), day post onset of symptoms 
(B) and Ct value (C) were assesed with a Mann Withney test. A Spearman correlation analysis was 
performed to assess the association between Ct value and TCR diversity.  
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We could compare the clonotypes found among fatal cases and survivors in order to observe 
to which degree they are interindividually shared. We could observe that survivors generally 
shared few clonotypes between them making most of their TCR repertoire mainly private. 
On the other hand fatal cases had a higher amount of shared sequences making theirs a 
more public TCR repertoire (Figure 4). These differences in the abundance of public and 
private TCR sequences could be of high relevance for the viral immune escape and the 
effectiveness of the immune response. 
 
Figure 4. Shared clonotypes in fatal cases and survivors. Clonotypes are defined as CDR3 sequences 
with identical aminoacid sequence. Heat maps show the number of shared clonotypes among fatal 
cases (left) and survivors (right). 
 
In order to investigate longitudinally the kinetics of the T cell response through the TCR 
diversity, we additionally obtained inverse Simpson index values as indicator of diversity 
from 5 fatal EVD cases and 5 EVD survivors at multiple time points during the course of the 
disease. Since the only temporal references we have on these samples is based on self-
reported onset of symptoms and thus not entirely accurate, we classified the samples in 
groups from day 1 to 5, 6 to 10 and more than 10 post onset of symptoms (Figure 5A). We 
performed a Mann Whitney test to assess the differences in the TCR diversity in fatal cases 
and survivors at each time point. Although there seems to be a tendency for TCR diversity in 
survivors to be higher at earlier time points and lower at later time points when compared to 
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fatal cases, we did not observe any statistically significant differences. The TCR diversity in 
the TCR response from survivors seems to expand faster and to be correlated to the 
decrease of viral load. On the other hand, TCR diversity in fatal cases seems to take longer to 
expand and is not associated with the control of viral replication (Figure 5B).  
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Figure 5. Longitudinal analysis of TCR diversity in EVD patients. A) Inverse Simpson index values of 5 
survivors and 5 fatal cases at different time points are shown. Samples were grouped depending on 
which day post onset of symptoms they were taken: 1 to 5, 6 to 10 or 11 to 15 days post onset of 
symptoms. B) The two top and two bottom graphs represent TCR diversity (green) and Ct values 
(black) of fatal cases and survivors, respectively and longitudinally over the course of the disease.  
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Discussion 
This is to our knowledge the first study focused on the effect of HLA polymorphism and TCR 
diversity on the severity of EVD disease. The novelty of this study is also attributable to the 
large amount of samples analyzed and to the capacity to evaluate longitudinally the 
dynamics of the TCR diversity over the course of the disease.  
The main conclusion that can be drawn from the association analysis made on HLA 
polymorphism is that there seems to be an heterozygous advantage associated to EVD. We 
observed a statistically significant association between HLA-A heterozygosity and survival 
which could indicate an enhanced capacity for these highly variable molecules to present a 
broader range of viral peptides activating a more diverse population of T cells and increasing 
the chances of the host to eliminate the virus. The fact that an HLA class I molecule is 
involved in this heterozygous advantage highlights the importance of CD8 T cells in the 
immune response to EVD. Previous results from our group in which fatal cases were 
correlated with an upregulation of T cell inhibitory markers CTLA-4 and PD-1 already show 
the importance of a well regulated CD8 T cell response during EBOV infection (Ruibal et al. 
2016).  
The importance of HLA polymorphism in CD8 T cell responses to EVD was already described 
in a previous study in which, although a small number of patients were investigated, alleles 
of the HLA-B locus B*67 and B*15 were associated with fatal outcome, whereas B*07 and 
B*14 were associated with nonfatal outcome (Sanchez et al. 2007). The elevated 
polymorphism that is characteristic of the HLA molecules makes it often necessary for a high 
number of samples to be compared in order to obtain statistical significance in the 
association analysis. We could analyze the allele frequencies in a population of over 200 
patients. Nevertheless, our results show no association between HLA allele expression and 
EVD outcome. The inclusion of a healthy control group to this study would have been highly 
informative to detect possible association of HLA alleles with protection or increased 
susceptibility to develop EVD upon exposure to EBOV. However, obtaining this type of 
samples was challenging in the context of the outbreak.  
Our conclusion on the heterozygous advantage of EVD is in agreement with our results 
obtained on the TCR diversity. A clear association was observed between high TCR diversity 
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and outcome indicating a broad T cell response, most likely activated by diverse HLA-peptide 
complexes, is correlated to survival. Moreover, when we observe the distribution of shared 
clonotypes among fatal cases and survivors we could observe that survivors express mainly 
private TCR sequences while the TCR repertoire from fatal cases is mostly public. It has been 
discussed that public sequences (i.e. shared sequences) present an evolutionary advantage 
to pathogens which are more likely to mutate in order to avoid recognition by these TCR 
sequences that are highly frequent in the host population (Kedzierska et al. 2006). This 
association between TCR diversity and viral escape has been observed in the case of SIV 
infection (Price et al. 2004). Therefore, a public TCR repertoire with limited diversity, as 
observed in EVD fatal cases, could have a decreased flexibility to confront variants in 
presented antigenic peptides, increasing the likelihood of immune escape.  
The longitudinal analysis of the TCR repertoire in fatal cases and survivors shows a 
correlation between TCR diversity and viral load. The timing of the TCR clonal expansion 
could be relevant for the clearing of the infection. Nevertheless, we are not able to 
determine whether these responses are induced by the amount of virus the patients were 
exposed to. It is plausible that a diverse TCR response is activated when viral loads are load 
and that a more restricted TCR response comes as a consequence of the inability of the 
immune response to cope with a higher initial viremia. 
During the last EVD outbreak in West Africa several studies were done on the genomic 
evolution of the virus through human to human transmission and its consequences on the 
efficacy of sequence based therapeutics (Kugelman et al. 2015). Moreover, important 
variations were observed within the GP protein of the EBOV (Carroll et al. 2015). In order to 
elucidate whether there is a link between the observations we made on the immunogenetics 
of EVD and the genomic variation of the virus further studies need to be done. The analysis 
of virus specific T cells should be developed to better understand the interactions between 
distinct viral epitopes and the repertoire of cytotoxic T cell responses, the timing of the 
immune response in relation to the viremia, as well as how viral evolution can be affected by 
the immune response. 
In summary, our study indicates that the host genetics might play an important role in the 
immune response to EBOV infection. In particular HLA-A heterozygosity might come as an 
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advantage for the host immune response. Moreover, TCR repertoire diversity favors viral 
clearance and survival to EVD. Altogether, our results further emphasize the relevance of 
CD8 T cells responses during EVD. 
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Discussion 
Despite its importance as human pathogen, the human immune response mechanisms to 
EBOV infection are poorly understood. A great amount of the knowledge we have today on 
the immune response to EVD comes from highly valuable experiments on animal models 
such as non-human primates and mice, but these findings cannot always be translated into 
humans. In vitro studies using human cells have also contributed to better understanding of 
cell-specific responses to EBOV infection, but cannot reproduce the complexity of immune 
physiology in living organisms.  
EBOV is an emerging zoonotic virus for which most of the human population is 
immunologically naïve. Due to this lack of pre-existing immunity, we hypothesized that the 
study of the relationship between antigen-presenting cells and T cells, which bridges innate 
and adaptive immunity, could provide important insight into disease pathophysiology 
(Banchereau & Steinman 1998).  
Immunophenotyping of blood samples collected from patients during the recent EVD 
epidemics in Guinea indicated that blood monocytes were significantly reduced  during EVD. 
These findings were consistent with the idea that the immune profiling of blood monocytes 
could serve as biomarker and disease monitoring tool. Previous in vitro studies have 
demonstrated that, during EBOV infection, activation of monocyte-derived dendritic cells is 
blocked by infection and their capacity to activate T cells is diminished (Yen et al. 2014; Bosio 
et al. 2003; Mahanty, Hutchinson, et al. 2003). Conversely, macrophages are highly activated 
by EBOV infection and contribute to inflammation and coagulopathy (Gupta et al. 2001; Bray 
& Geisbert 2005; Caballero et al. 2016; Thomas W. Geisbert et al. 2003). Our first 
observation was a significant decrease in the amount of circulating monocytes in EVD 
patients compared to EVD negative patients (Lüdtke et al. 2016). This decrease was more 
remarkable in CD16+ monocytes, a cell subset relevant for antiviral immunity due to their 
ability to patrol blood vessels and recognize viral RNA (Serbina et al. 2008; Cros et al. 2010). 
Moreover, this decrease was more striking in patients with high viremia. One possible 
explanation for the loss of circulating monocytes could be their direct infection and death. 
The capacity of EBOV to infect monocytes has long been discussed since some studies have 
shown the productive infection of human blood derived monocytes with EBOV while others 
evidence a restricted GP-mediated entry of EBOV into monocytes (Ströher et al. 2001; 
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Yonezawa et al. 2005; Dube et al. 2010). This controversy has been perhaps clarified by a 
recent study indicating that, while immature monocytes were refractory to EBOV entry, 
activated monocytes supported high levels of virus replication (Martinez et al. 2013). During 
our field studies we failed to demonstrate infection of monocytes but recent studies from 
our laboratory indicate that in fact, inflammatory monocyte-derived DCs are primary EBOV 
target cells and may contribute to virus dissemination (Lüdtke et al. 2017). 
A second possible explanation for the reduced number of monocytes observed in the 
peripheral blood of EVD patients with high viremia could be extravasation to the sites of 
infection. Monocytes are antigen presenting cells that circulate in the peripheral blood with 
patrolling behaviour and migrate to the tissue under inflammatory conditions, where they 
differentiate into inflammatory dendritic cells and macrophages (Cros et al. 2010; Auffray et 
al. 2007). This is actually in line with the hypothesis that monocyte-derived DCs may act as 
virus “vessels” and contribute to dissemination. This hypothesis however, needs to be tested 
in relevant animal models of disease. A similar process has been observed in the case of 
Dengue virus (DENV) infection in which monocytes are recruited to the site of infection and 
they are differentiated into monocyte-derived dendritic cells becoming major targets of 
DENV infection (Schmid & Harris 2014). This strategy allows the virus to increase their 
cellular targets of infection by exploiting the antiviral immune response. Whether this 
mechanism is promoted by EBOV remains to be determined in vivo.  
When we classified patients depending on their outcome we observed that the decrease in 
the amount of CD16+ monocytes was also significant when patients suffered a fatal disease 
compared to those who survived (Lüdtke et al. 2016). This observation indicated an 
association between the levels of circulating CD16+ monocytes and EVD outcome. We 
further analysed the activation status of monocytes by measuring surface levels of HLA-DR. 
The expression of HLA-DR has been associated to the activation of monocytes during 
infection and inflammation (Diao et al. 2014). We could observe that there was a 
significantly higher activation of monocytes in the case of survivors compared to fatal cases. 
Moreover, the higher activation of monocytes was correlated with viral clearance in the 
analysis of the patients’ response longitudinally over the course of the disease. This finding 
implies that CD16+ monocytes may play an important role in the immune response to EBOV 
and in viral control. Moreover, this work evidences an immune suppressive mechanism of 
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EBOV infection on monocyte function, which correlates well with previous in vitro data 
(Bosio et al. 2003; Mahanty, Hutchinson, et al. 2003).  
The second part of this thesis was focused on the specific role of T cells during EVD. T cells 
play a crucial role in the elimination of viral infections. Naïve CD8 T cells are activated by 
antigen presenting cells and are able to eliminate virus-infected cells. The effect of EBOV 
infection on the human T cell population has been controversial. Early studies have 
described that EVD is accompanied by massive lymphocyte apoptosis (Baize et al. 1999; 
Gupta et al. 2007; Wauquier, Becquart, et al. 2010). This could be explained by the lack of 
stimulation from EBOV infected dendritic cells which leads to the inability of the host to clear 
the infection (Bosio et al. 2003). On the other hand, more recent reports show that there 
could be lymphocyte proliferation preceding lymphopenia evidencing that the dynamics of T 
cell kinetics during EVD are more complex and need further study for a better understanding 
(Wolf et al. 2015; Kreuels et al. 2014).  
With the use of multiparametric flow cytometry analysis of peripheral blood samples, we 
evaluated the T cell responses of EVD patients through the analysis of expression levels of 
specific markers for cell activation or inhibition. This technology allowed an increased 
resolution in the information obtained by performing the analysis of parameters at the 
single cell level. Contrary to what was previously reported we did not observe any 
lymphopenia in EBOV-infected patients. Indeed, elevated co-expression of HLA-DR and CD38 
on both CD4 and CD8 T cell indicated robust T-cell activation in EVD patients (Ruibal et al. 
2016). The co-expression of these markers was elevated in both fatal cases and survivors 
indicating there is no association between the capacity of the host to activate T cell 
responses and the outcome to the disease. The expression of these markers has been 
associated with the activation of T cells through TCR signalling indicating that there is 
functional T cell priming and activation by antigen presenting cells during EVD in humans 
(Appay et al. 2002; Miller et al. 2008). The lack of lymphopenia in the patients included in 
our study compared to previous outbreaks could be related to the infection with the new 
EBOV Makona strain which caused the last EVD outbreak in West Africa. A recent 
comparative infection study between Makona and Mayinga strains of EBOV in non-human 
primates evidenced similar lymphopenia and other pathological features of EVD with both 
strains with a decreased virulence for Makona EBOV manifested in a delayed disease 
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progression (Marzi et al. 2015). These observations support the idea that lymphopenia 
occurs at later time points and that we do not observe lymphopenia because of the lack of 
available longitudinal sampling in fatal cases. The decreased virulence of the Makona strain 
could also be an explanation for the capacity of the patients to initially prime naïve T cells 
regardless of disease outcome. 
To better understand the relationship between inflammation and T-cell phenotype, the 
expression of pro-inflammatory cytokines and chemokines was measured in plasma samples 
with multiplex ELISA in the BSL4 laboratory in Hamburg. We observed higher levels of TNF-α, 
MIP-1α, MIP-1β and MCP-1 in fatal cases compared to survivors consistent with the 
expression of activation markers. This is in agreement with another report from the last EVD 
outbreak in West Africa in which high activation of T cells was observed for up to 60 days 
post onset of symptoms, indicating persistence of viral antigen continuously stimulating the 
response (McElroy et al. 2015). In the same study, an important activation of B cells was also 
observed with the generation of EBOV specific IgG. It is worth noting that the observation 
done during these two studies correspond to patients receiving supportive care or 
experimental therapeutics respectively, indicating that T cell activation is a feature of EVD 
regardless of treatment. The higher expression of pro-inflammatory cytokines and 
chemokines observed in fatal cases evidence the important role of inflammation during EVD 
pathogenesis that leads to poor outcome and suggests that the regulation of inflammatory 
responses is crucial for recovery. 
The regulation of the immune response is of great importance to avoid inflammation-related 
immunopathology. There are several mechanisms available for the organism to regulate 
including regulatory T cells which compete with naïve T cells in interactions with APCs, 
hindering the activation of T cells by dendritic cells. Moreover, these cells produce 
immunosuppressive cytokines such as IL-10 and TGF-β to inhibit the function of T cells 
(Sakaguchi et al. 2008).  Another way of regulating the T cell response is through the 
expression of inhibitory markers such as CTLA-4 and PD-1. CTLA-4 intrinsically regulates T cell 
activation by competing with CD28 for the interaction with the co-stimulatory receptors 
CD80 and CD86 on the surface of antigen presenting cells. CTLA-4 binds CD80 and CD86 with 
higher affinity than CD28 sending an inhibitory signal that limits the proliferation of T cells 
(Egen et al. 2002). PD-1 also mediates a T cell intrinsic mechanism of immune regulation by 
84 
 
binding its ligands PD-L1/PD-L2 and suppressing the TCR signalling (Okazaki et al. 2013). 
These two mechanisms are essential for the maintenance of immune homeostasis and for 
autoimmune control (Parry et al. 2005). 
Dysregulation of T-cell homeostasis mechanisms is a complex topic and has been 
investigated mainly in the context of persistent inflammation (i.e. chronic infection and 
cancer). These studies have demonstrated that sustained expression of CTLA-4 and PD-1 is 
correlated with progressive loss of function in effector cells, a phenomenon that has been 
called “T-cell exhaustion” (Wherry 2011). It is not clear whether T-cell exhaustion also occurs 
during acute infection. However, dysfunctional T-cell activation associated to high levels of 
CTLA-4 and PD-1 expression has been described in several acute infections including malaria, 
hantavirus, influenza and Dengue virus infections (Hafalla et al. 2012; Lindgren 2011; 
Ayukawa et al. 2004; Chen et al. 2009). Despite the fact that we could not conduct functional 
T cell studies in the field, we observed that the expression levels of both CTLA-4 and PD-1 
were significantly upregulated in fatal EVD cases compared to survivors indicating an 
association between expression of these markers and poor outcome  (Ruibal et al. 2016).  
This idea was further supported by multiplex ELISA analysis which showed significantly 
higher levels of the anti-inflammatory cytokine IL-10 in fatal cases compared to survivors. 
Notably, we were able to show that T cells expressing CTLA-4 were also activated and 
expressed HLA-DR and CD38, suggesting the initiation of T cell intrinsic mechanisms of 
immune homeostatic regulation upon T-cell activation. Additionally, we observed a 
significant positive correlation between the expression of CTLA-4 and the viral load, 
indicated by Ct value, a strong predictor of disease outcome (Lanini et al. 2015). This 
observation indicates a possible state of exhaustion and loss of effector function of inhibited 
T cells, making them incapable of controlling viral replication. This inability of the host to 
eliminate the virus exacerbates the inflammatory response which further decreases the 
chances of recovery. Nevertheless, whether functionally inhibited T cells are unable to 
control viral replication or, inversely, an elevated viral load is overwhelming the T cell 
response cannot be concluded from our results.  
Interestingly, upregulation of the expression of CTLA-4 and PD-1 has been also recently 
observed in other acute infections such as malaria. In this case, it was observed that 
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infection promoted the formation of a population of IL-10-producing Foxp3-negative 
regulatory T cells with ability to prevent activation of bystander T cell clones (Mackroth et al. 
2016). These findings match well with our observations of higher expression of IL-10 in fatal 
EVD cases and with reduced clonal expansion in these patients.  
The formation of EBOV specific CD8 T cells was traced with the use of dextramers designed 
for MHC-I alleles commonly expressed in the West-African population, such as HLA-A*02:01, 
HLA-A*23:01 and HLA-B*35:01, bound to EBOV-NP derived peptides with high affinity for 
the corresponding alleles (Modiano et al. 2001). We chose to use peptides derived from 
EBOV-NP since it has been previously shown that this protein drives most of the CD8 T cell 
responses (Sundar et al. 2007; Simmons et al. 2004). The HLA alleles used for dextramer 
design were identified in patients via sequencing of the HLA locus. We focused our analysis 
on 6 patients for which we could obtain several samples during the course of the disease for 
a longitudinal evaluation of the EBOV-specific CD8 T cell response. These included two fatal 
cases and four survivors. We observed that there were no significant differences in the 
percentage of virus-specific T cells between fatal cases and survivors at the time of 
admission to the Ebola treatment center (Ruibal et al. 2016). Interestingly, in later stages of 
the infection patients who survived showed an increased frequency of EBOV-specific CD8 T 
cells while fatal cases did not. The generally small amount of EBOV-specific T cells detected 
with the use of dextramers did not allow us to significantly evaluate the expression of 
activation or inhibitory markers on these cells making it not possible for to us determine the 
activation status of these cells. Notably, in the case of survivors the formation of EBOV-
specific T cells was accompanied with viral clearance, a decrease in the expression of CTLA-4 
and PD-1 and contraction of activated HLA-DR+CD38+ T cells. On the other hand, fatal cases 
showed poor formation of EBOV-specific CD8 T cells associated to high viremia and 
sustained expression of CTLA-4 and PD-1 until death. A possible explanation for this result 
could be high expression of CTLA-4 leading to T cell extrinsic inhibition of EBOV-specific T 
cells, impairing the host capacity to clear the virus. Mechanisms that could be involved in 
this cell extrinsic regulation are the trans-endocytosis of CD80 and CD86 co-stimulatory 
molecules and the modulation of the activity of regulatory and effector T cell populations 
(Qureshi et al. 2011; Walker & Sansom 2011; Corse & Allison 2012). Once again, it is not 
possible to establish whether the high viral load overthrows the immune response or 
conversely, if it is an inhibition of the T cell effector function which makes it impossible to 
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control viral replication. Nevertheless our results strongly suggest that the balance between 
immune regulation and an effective virus-specific T cell response play an important role in 
recovery from EBOV infection. Functional studies are necessary to better understand the 
mechanisms involved in the immune regulation during EVD and to test whether they could 
be used as therapeutic targets. 
The observed dysregulation of the cytokine and chemokine responses during human EVD, 
with elevated expression of pro-inflammatory cytokines and chemokines as well as anti-
inflammatory cytokines in fatal cases has been already described (Hutchinson & Rollin 2007; 
Gupta et al. 2012; Wauquier, Becquart, et al. 2010; Baize et al. 2002; Villinger et al. 1999). A 
study performed on asymptomatic human cases of EBOV infection showed that an early and 
strong pro-inflammatory response followed by a regulatory anti-inflammatory response was 
accompanied by clearance of virus infected cells through cytotoxic mechanisms (Leroy et al. 
2000; Leroy et al. 2001). It is likely that the lack of control of viral replication leads to a 
constant stimulation of the innate immune response and a dysregulation of the cytokine 
response which, in turn, could facilitate viral dissemination via recruitment of virus target 
cells such as activated monocytes to the sites of infection. 
The data obtained during this work evidence that there is a general inhibition and 
dysregulation of the immune response during fatal human EVD characterized by poor 
monocyte activation and elevated expression of T cell inhibitory markers CTLA-4 and PD-1 
which, regardless of the robust activation of T cells observed in patients, is accompanied by 
an inability to control viral replication. Proper activation of the antiviral adaptive immune 
response by cells of the innate immune response is crucial for the control of viral infection. 
The clear alteration in these processes during EVD lead us to further investigate the specific 
roles of molecules involved in the immunological synapse, the interface between the innate 
and the adaptive immunity, in particular the HLA molecule and the T cell receptor (TCR). 
Both molecules show extensive diversity which is fundamental for their function. In order to 
evaluate the impact of their diversity in the context of the immune response against EBOV 
infection we obtained genomic DNA from whole blood leftover diagnosis samples from over 
200 patients for the sequencing of HLA class I and II alleles as well as the CDR3 region of the 
TCR β chain, which is the part with highest variability in the region that determines antigen 
recognition.  
87 
 
The extensive polymorphism at the HLA class I and II loci makes homozygosity rare. The main 
function of the HLA molecule is to present antigenic peptides to activate T cell responses. 
Therefore, HLA diversity is directly associated with the capacity to elicit a more diverse T cell 
response against pathogens. HLA diversity has been extensively studied in the context of 
infectious diseases and associations have been established between HLA polymorphisms and 
disease susceptibility. For instance, faster HIV progression has been associated with HLA 
class I homozygosity meaning that the expression of a wider variety of HLA molecules, which 
is the case in heterozygosity, leads to protection (Martin & Carrington 2013; Carrington 
1999). Similarly, HLA class II homozygosity was associated with an increased risk of HBV 
persistence (Thio et al. 1999; Thursz et al. 1997).  
For the analysis of the HLA diversity in this study, we sent all genomic DNA samples that 
were available to us to Mary Carrington’s team at NIH for high resolution genotyping of HLA 
classes I and II. We first analyzed the possible association of zygosity with disease outcome 
and we observed a significant association between HLA-I homozygosity and outcome. 
Specifically we observed correlation between homozygosity of the HLA-A allele and fatal 
EVD. These results suggested that CD8 T-cell immunity, activated through HLA-class I antigen 
presentation may play an important role in controlling EBOV replication. The higher diversity 
in this response, given by the heterozygosity could be critical for the host to resist to a 
broader range of variants of infectious pathogens. This phenomenon was observed in the 
case of HIV infection, in which HLA diversity was associated with the capacity of cytotoxic 
lymphocytes to respond to a larger proportion of epitopes (Scherer et al. 2004). Another 
possible explanation could be that HLA polymorphism has an effect on viral fitness in which 
the virus is more likely to adapt and become resistant in the presence of more common 
alleles, such as the case of allele homozygosity. Heterozygous individuals might have an 
advantage to control the infection since they are more likely to carry more rare alleles to 
which the virus could not adapt. An example on how the interaction between the virus and 
the host immune response can affect viral adaptation is available once again for HIV and 
HCV infections (Carlson et al. 2015; Plauzolles et al. 2013). The possibility of EBOV 
adaptation to the human immune response has been addressed on the basis of multiple 
substitution mutations that were observed in virus isolates from the last EVD outbreak in 
West Africa compared to earlier outbreaks (Gire et al. 2014; Basler 2014). However, further 
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monitoring of viral genetic changes coupled to epidemiological data and functional studies is 
needed in order to understand the effect of genetic variations in the virus behaviour. 
Additionally, specific HLA alleles have also been associated with increased susceptibility or 
protection to viral infections such as HIV and HBV (Martin & Carrington 2005). In the case of 
EVD infection, alleles B*67 and B*15 were associated with fatal outcomes, whereas B*07 
and B*14 were associated with nonfatal outcomes highlighting the importance of HLA 
repertoire and CD8 T-cell response during SUDV infection (Sanchez et al. 2007). From the 
data that we collected from the last EVD outbreak in West Africa, we did not observe any 
significant associations between the expressions of specific HLA alleles and disease outcome. 
Since some of the alleles might show a tendency to be expressed more frequently in either 
fatal cases or survivors, and because of the high polymorphism of the HLA loci, it would be 
interesting to enlarge the number of patient samples in order to confirm our results. 
Nevertheless, the lack of association that we observe between the HLA allele expression and 
disease outcome could suggest that none of them present an improved capacity to activate 
an effective cytotoxic T cell. This would further support our observations about the 
importance of an adequate regulation of the adaptive immune response in order for the 
host to clear the virus and recover from EVD. 
As mentioned previously, TCRs are also crucial for the communication between the innate 
and adaptive immune responses. TCRs also present an important level of polymorphism in 
order to be able to recognize the large variety of antigenic peptides presented by the HLA 
molecules. This recognition leads to the activation of T cells which are important players in 
the control and elimination of viral particles. The importance of TCR diversity during 
infectious diseases has been demonstrated in the context of SIV infection in which viral 
escape from the immune system occurred more easily in the presence of T cell populations 
with highly conserved CDR3 regions (Price et al. 2004). Moreover, the elevated presence of 
shared sequences among the host population also represent an evolutionary advantage to 
pathogens, which are more likely to mutate in order to avoid recognition by these TCR 
sequences (Kedzierska et al. 2006). Our analysis of the TCRβ CDR3 sequences from 22 EVD 
fatal cases and 18 EVD survivors show that there is a significant association between higher 
TCR repertoire diversity and survival to the disease. When correlating Ct value and TCR 
diversity we observed that there is a positive correlation between the two values indicating 
89 
 
that a higher TCR diversity is associated with lower viral load, a strong indicator of disease 
outcome. Moreover, when we observe the distribution of shared clonotypes among fatal 
cases and survivors we could observe that survivors express mainly private TCR sequences 
while the TCR repertoire from fatal cases is more widely shared. All of these observations 
inferred from the sequencing of the TCR repertoire in EVD patients highlight the importance 
of the development of a diverse TCR response in the host for the control of viral replication. 
The lack of TCR diversity in fatal cases, both intrapersonal and interpersonally, represent an 
increased probability for the virus to escape the host immunity. This information is highly 
relevant and should be taken into account during the development of efficient vaccines, 
which should be designed with epitopes that are able to elicit a diverse T cell response in 
order to minimize the chances of viral immune escape.  
In conclusion, the elevated TCR repertoire diversity might allow a better communication 
between the innate and adaptive immune responses. In survivors, the proper activation of 
monocytes probably leads to an early T cell response which is capable of controlling the viral 
replication before regulatory events come into play. The use of immunotherapy to enhance 
the innate immune response or to better regulate the adaptive immunity should be taken 
into account for future studies in animal models. Further analysis should be performed to 
evaluate the immunodominance of T cell responses and to try to identify relevant T cell 
clones which could be potentiated with the use of vaccines.  
In a mouse model for malaria treated with anti-CTLA-4 results were obtained in which the 
expression of CTLA-4 protected the animals from a cerebral form of the disease (Haque et al. 
2010). The blockade of CTLA-4 and PD-1 is approved and extensively used for the treatment 
of melanoma and lung cancer which resulted in tumor-specific T cell activation, control 
tumor growth and increased survival (Buchbinder & Desai 2016). Still, the use of antibodies 
to block CTLA-4 and PD-1 pathways has been associated with the development of immune-
related adverse events caused by the lack of regulation of the immune response (Michot et 
al. 2016). From our observation on the upregulation of the expression of CTLA-4 and PD-1 
during fatal cases of human EVD, the use of antibodies against these receptors as an option 
of immunotherapy upon exposure to EBOV should be explored.  For this, the use of animal 
models of EVD such as a chimera mouse model with competent hematopoietic immunity 
would be necessary and highly valuable (Lüdtke et al. 2017). The expression of CTLA-4 and 
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PD-1 inhibitory markers during the EBOV infection of these animals should be determined 
and correlated to viral loads and outcome in order to establish that this is an appropriate 
model for immunotherapy experiments. 
Dendritic cell function can also be modified through the use of antibodies and the direct 
delivery of antigens or molecules to enhance or inhibit their immune activation (Klechevsky 
& Banchereau 2013). Particularly, the use of soluble CD40L (sCD40L) has been used to 
enhance the DC-mediated immune activation of T cells in the context of oncology and 
infectious disease (Kornbluth & Bot 2012). In the case of vesicular stomatitis virus infection, 
agonistic CD40 stimulation was achieved with the use of anti-CD40 antibodies resulting in an 
enhanced T cell response (Zickovich et al. 2014). In the context of EVD, increased levels of 
sCD40L were associated with survival in SUDV infected patients (McElroy et al. 2014). A 
possible explanation for this is sCD40L promotes the activation of dendritic cells (Martinson 
et al. 2004). This knowledge together with the association we observed between severe 
disease and the poor activation status of circulating antigen presenting cells in human EVD 
encourages the exploration of the use of monocytes as potential targets for immunotherapy. 
Our observations on the importance of monocyte activation for viral clearance and recovery 
should encourage the study of the enhancement of the monocyte activated status as 
therapeutic approach to EVD. 
Another therapeutic approach that could be explored against EBOV infection is the blockade 
of cellular receptors that are important for EBOV entry in dendritic cells and macrophages. 
This way the pathology derived from the inhibition of dendritic cells or the massive 
inflammatory responses from macrophages infected with EBOV could be avoided allowing 
the development of more efficient T cell responses. DC-SIGN is one important receptor for 
EBOV entry that could be targeted with antibodies or other compounds in order to reduce 
viral entry. For example, a glycodendritic structure has been developed to block interaction 
between EBOV and DC-SIGN in vitro (Lasala et al. 2003).  
The results obtained during this study demonstrate the importance of both the innate and 
the adaptive immune responses for EVD survival in humans. Our results evidence an immune 
suppressive mechanism of EBOV infection on monocyte function which leads to disease 
pathophysiology. The proper activation of these cells was associated with better outcome, 
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making them potential targets for immunotherapy through the use of diverse molecules, 
such as sCD40L, to enhance their activity. The robust activation of T cells was observed 
regardless of disease outcome. However, the regulation of the T cell responses seems to be 
crucial for an enhanced survival. We observed that both CD4 and CD8 T cells from EVD fatal 
cases significantly upregulate the expression of the inhibitory markers CTLA-4 and PD-1, 
which could be leading to an exhausted phenotype of these cells making them unable to 
control viral replication in the host. Taken together, fatal EVD is associated with a reduction 
in the amount of circulating monocytes which in turn exhibit a low activation profile. The 
dysregulation of the T cell immune response leads to a lack of control of viral replication 
which in turn exacerbates the inflammatory response contributing the disease 
pathophysiology. On the other hand, survivors display a proper activation of monocytes 
accompanied by a robust and well regulated T cell activation which is associated to viral 
clearance. In these cases the inflammation seems to be restrained and the patients recover. 
We obtained no evidence of association of survival with the expression of any specific HLA 
allele. However heterozygosity at the HLA-A locus was significantly associated with survival 
supporting the important role of CD8 T cell responses during EVD disease. Moreover, the 
study of TCR repertoire diversity demonstrated that survival is significantly associated with 
an elevated TCR diversity as well as with a lower amount of shared TCR sequences between 
individuals.  
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Materials and methods 
Patients and samples 
All samples were obtained from leftover blood corresponding to patients that were 
diagnosed at the Ebola Treatment Centres (ETC) in Guéckédou and Coyah, Guinea, between 
March 2014 and July 2015. Diagnosis of EVD was done on EDTA-blood samples using the 
RealStar Zaire Ebolavirus RT-PCR Kit 1.0 (Altona Diagnostics) by the European Mobile 
Laboratory (www.emlab.edu). Samples were transferred into our laboratory at Donka 
Hospital in Conakry and utilized for immune analyses. Initial processing of the samples until 
inactivation was safely done in a class III cabinet “glovebox” equipped with negative 
pressure. First, plasma was separated from blood cells via sedimentation. Red blood cells 
were then lysed with red blood cell (RBC) lysis buffer diluted in water for 10 minutes at RT. 
Cells were washed with PBS and either carefully stored with 10% DMSO or directly stained 
for flow cytometry analysis. The study corresponding to publication I included 28 patients 
with acute EVD and 34 EVD-negative febrile controls with a median age of 34 years 
(interquartile range 20-43 years). In the case of publication II, the study included first 47 EVD 
positive patients and 61 EVD negative patients from which 53% were female and 70% were 
18 years old or older, and later analysis included 157 EVD positive patients were 54,14% 
were female and 78,98% were 18 years old or older, with a median age of 26 years 
(interquartile range 20–38 years) 
 
Flow cytometry 
For the flow cytometry staining performed at Donka Hospital (publications I and II), cells 
were first blocked with Fc Receptor Blocking Solution (BioLegend) for 10 minutes at RT to 
avoid unspecific binding of antibodies. Cells were centrifuged at 2000 rpm for 5 minutes and 
surface staining was then performed by resuspending the cell pellets in the mix of antibodies 
and incubating for 30 minutes at RT. Samples were then inactivated with Cytofix/Cytoperm 
buffer (BD) containing 4% formaldehyde for another 30 minutes at RT, followed by staining 
with intracellular antibodies (CD3, CTLA-4 and Ki-67) for 30 minutes at 4°C. Sample 
acquisition was done in a Guava easyCyte 8 Flow Cytometer from Millipore. The different 
antibody panels used are indicated in tables 1 and 2. 
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Table 1. Panel for myeloid populations in peripheral blood using the 3-laser Guava 
Laser  Marker Color 
Violet (405 nm) CD11c PB 
CD14 BV 510 
Blue (488 nm) EBOV GP FITC 
CD141 PE 
CD3, CD19, CD56 PerCP/Cy5.5 
HLA-DR PE/Cy7 
Red (633 nm) CD1c APC 
CD16 APC/Cy7 
 
Table 2. Panel for lymphoid populations in peripheral blood using the 2-laser Guava. Due to the 
limited number of parameters that could be measured in one panel, several panels were designed in 
which the lymphocyte population markers CD3, CD4 and CD8 were always maintained while 
activation and inhibition markers were measured in separate stainings. 
Laser Marker Color 
Blue (488 nm) CD4 FITC 
CTLA-4 (CD152) / Ki-67 (intracellular) PE 
HLA-DR / PD-1 (CD279) PerCP/Cy5.5 
CD8 PE/Cy7 
Red (633 nm) CD38 APC 
CD3 (intracellular) APC/Cy7 
?
The cells stored and transported to the BSL-4 in Hamburg (publication II) were analyzed for 
co-expression of markers. For this, samples were first thawed at 37°C and the sample 
volume transferred to ice-cold 15 ml falcon tubes where 5 ml ice-cold R8 medium (RPMI + 
8% FBS) were added. Sample tubes were then centrifuged to remove the cryopreservant 
(10% DMSO) 1000 rpm for 10 minutes and resuspended in R8 medium. Samples were 
centrifuged once more and the pelleted cells were washed with 12 ml of ice-cold R8 
medium. The staining procedure was the same as mentioned above with the addition of a 
first step of live/dead staining (Zombie NIR from Biolegend) for 20 minutes at RT, previous to 
blocking. For some samples in which dextramer staining was also possible, cells were 
incubated in a 1/10 dilution of the dextramer for 30 minutes at 37°C prior to any other 
staining. Samples were acquired in a LSR Fortessa instrument (BD). The antibody panel used 
is indicated in table 3.  
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Table 3. Panel for lymphoid populations in peripheral blood using the LSR Fortessa instrument. 
With a higher number of parameters that we could measure with the LSR Fortessa, coexpression of 
activation and inhibition markers could be analyzed in the lymphocyte population. A live/dead 
staining which permeates only through compromised membranes was also possible in order to 
identify live cells. Moreover, dextramer staining could be done on samples for which HLA type was 
defined, allowing the detection of EBOV specific T cells. 
Laser  Marker Color 
UV (355 nm) CD4 BUV395 
Yellow/Green (561 nm) HLA-DR PE/Cy7 
CTLA-4 (CD152) (intracellular) PE 
Violet (405 nm) CD38 BV785 
CD8 BV650 
PD-1 (CD279) BV605 
CD3 (intracellular) BV510 
Ki-67 (intracellular) BV421 
Red (640 nm) Live/Dead APC/Cy7 
Dextramer APC 
 
In silico peptide analysis and dextramer design 
MHC dextramers were designed for the detection of EBOV-specific T cells (publication II). 
EBOV NP derived peptides with high affinity (IC50<50) for MHC alleles commonly expressed 
in the West African population such as HLA-A*02, HLA-A*23 and HLA-B*35 were selected. 
IC50 values for peptide binding to MHC were predicted by the artificial neural network (ANN) 
at the Immune Epitope Database and Analysis Resource (IEDB) (www.iedb.org). Two 
additional matrix-prediction algorithms, BIMAS (http://www.bimas.cit.nih.gov) and 
SYFPEITHI (http://www.syfpeithi.de), were used to verify the selected peptides. Peptides 
predicted by all three bioinformatic tools were screened for similarity to the human genome 
using the NIH Blast server (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Only peptides showing 
no homology to the human proteome were used for the production of dextramers. All 
dextramers were purchased from Immudex. The dextramers background signal was 
determined by staining of MHC-matched healthy donors peripheral blood mononuclear cells 
(PBMCs). Additionally, a fluorescent minus one (FMO) control was performed.  
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Isolation of DNA  
DNA was isolated from whole blood using TRIzol Reagent and according to the 
manufacturer’s instructions. Briefly, approximately 70 μl of whole blood was homogenized in 
1 ml of TRIzol reagent. Homogenized samples were stored at -80°C. For extraction, samples 
were thawed and incubated at room temperature (RT) for 5 minutes. 0,2 ml of chloroform 
was added to the samples which were then shaken and incubated for 3 minutes at RT. The 
samples were then centrifuged at 10600 rpm for 15 minutes at 4°C during which the mixture 
separates into two phases, the upper aqueous phase containing the RNA and the lower 
phenol-chloroform phase containing DNA and protein. The aqueous phase was discarded 
and DNA was precipitated from the phenol-chloroform phase by adding 0,3 ml of 100% 
ethanol to the phenol-chloroform phase. The mix was incubated for 3 minutes at RT and 
then centrifuged at 4400 rpm for 5 minutes at 4°C. The phenol-ethanol supernatant was 
discarded and the DNA pellet was then washed twice with 1 ml of 0,1 M sodium citrate in 
10% ethanol incubated for 30 minutes at RT. The sample was then centrifuged at 4400 rpm 
for 5 minutes at 4°C and the DNA pellet was resuspended in 1,5 ml of 75% ethanol. After 15 
minutes incubation at RT the sample was centrifuged again, the supernatant was discarded 
and the DNA pellet was air dried for 10 minutes before resuspension in 50 μl 8mM NaOH. 
DNA samples were stored at -20°C. 
 
HLA genotyping and count of allele frequency 
For HLA genotyping genomic DNA samples extracted from whole blood of EVD patients was 
used. These samples were sent to Dr. Mary Carrington’s team at the National Cancer 
Institute in Frederick, United States of America, where they performed high resolution 
genotyping for HLA. For this, PCR–sequence-based typing, as recommended by the 13th 
International Histocompatibility Workshop (available at: 
http://www.ihwg.org/tmanual/TMcontents.htm) was used. HLA sequences were analyzed 
using the ASSIGN software (Conexio Genomics). 
For the calculation of allele frequencies in fatal cases and survivors a simple count of alleles 
was done. If there are two alleles at each locus, H and h, then there are three possible 
combinations for these: one heterozygote (Hh or hH) and two homozygotes (HH and hh). In 
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the case of the HLA loci, since there are multiple possible alleles the frequency of each is 
calculated by counting its presence or absence. For example, to obtain the frequency of HLA-
A*02 at locus HLA-A, A2 would be the presence of HLA-A*02 and X would be the presence of 
any allele except HLA-A*02.  
Table 4. Distribution of the HLA-A*02 allele in fatal cases of EVD. 
Genotype A2:A2 A2:X X:X 
Observed individuals 6 31 86 
Amounts of allele A2 12 31 0 
Amounts of allele X 0 31 172 
 
Since this count is done in 123 patients, there are 246 alleles at the HLA-A locus and the 
allele frequency of HLA-A*02 is calculated as (12+31)/246=0,17 and the frequency sum of all 
the alleles except HLA-A*02 is (31+172)/246=0,83, being the sum of both frequencies 1. Only 
alleles for which a minimal frequency of 2% was observed were taken into account for 
association analyses.  
 
TCR amplification, amplicon purification and library construction 
TCR sequences were obtained by amplifying the TCR β CDR3 loci from samples of genomic 
DNA. The TCR library was generated with the use of Multiplex PCR using 45 forward primers 
each specific to a functional TCR Vβ segment and 13 reverse primers each specific to a TCR 
Jβ segment (Robins et al. 2009). Multiplex PCR amplification was performed in two steps of 
PCR, a first one which allows the inclusion of adapter sequences which are recognized by the 
primers during the second step of PCR. The second PCR then adds indices for sample pooling 
as well as Illumina sequencing adapters (Figure 1). 
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Figure 1. Multiplex PCR amplification workflow. The TCR β CDR3 was amplified in a first step of PCR 
with the use of region of interest-specific primers with overhang adapters. In a second step of PCR 
Nextera XT indices and Illumina sequencing adapters are added with the use of primers specific for 
the adapter sequences.  Once the samples are indexed they can be normalized and pooled and the 
library is ready for sequencing. 
For the first step of PCR amplification two sets of primers were used: a first set with all 
primers with overhang adapter sequences and another without adapter sequences. The 
combination of both sets of primers showed an advantage for fragment amplification since 
primers without overhang adapter sequences probably anneal better to the template 
sequence and provide a higher concentration of pre-amplified template for primers with 
overhang adapter sequences to recognize. Forward and reverse primers with and without 
overhang adapter sequences were pooled separately to a final stock of 10 μM each. 
Multiplex PCR reactions were carried out with the Qiagen Multiplex PCR Kit (Ref. 206143) in 
a final volume of 25 μl per reaction which included 1 μl of DNA template, 12,5 μl of 2x 
Multiplex PCR Master Mix, 0,5 μl of each pool of forward and reverse primers without 
adapter sequences, 2,5 μl of each pool of forward and reverse primers with adapter 
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sequences, 3 μl of DNase free water and 2,5 μl of Q solution. The PCR cycle  was initiated by 
a 15 minutes step of activation of the HotStartTaq DNA Polymerase at 95°C. Next, 
denaturation at 94°C for 30 seconds was followed by annealing for 90 seconds at 69°C, with 
touchdown PCR of 1°C reduction of the temperature for the first 10 cycles. After extension 
at 72°C for 90 seconds, 40 cycles (10 cycles for touchdown + 30 cycles) of denaturation, 
annealing, and extension followed. A final extension at 72°C was performed for 10 minutes.  
The PCR products were purified with the use of Agencourt AMPure XP reagent (Ref. A63881) 
and following the manufacturer’s instructions. This reagent includes paramagnetic beads 
which selectively bind DNA fragments allowing the removal of excess primers, nucleotides 
and enzymes with a simple washing step. Moreover, the DNA to beads ratio allows the 
purification of amplicons with a specific size. For this study, the PCR products were mixed to 
1,8x volume of beads for the recovery of amplicons of about 200bp. The mixes placed in 0,5 
ml eppendorf tubes were vortexed, spinned and incubated for 5 minutes at RT. Beads bound 
to DNA were pelleted by placing the tubes in a magnetic rack (Dynamag-2 magnet), allowing 
the supernatant to be discarded and beads to be washed twice with 70% ethanol. The 
supernatant was completely removed and the bead pellets were air dried for 5 minutes 
before eluting the DNA with 50 μl of endotoxin free water. This purified DNA was used as a 
template for the second step of PCR. 
For the second step of PCR the Nextera XT Index kit (Ref. FC-131-1001) was used to add dual 
indices and Illumina sequencing adapters. The addition of indices to the amplicons allows 
the identification of each sample when pooling them together for the final sequencing step. 
PCR reactions were carried out with the Qiagen Multiplex PCR Kit (Ref. 206143) in a final 
volume of 25 μl per reaction which included 5 μl of DNA template, 12,5 μl of 2x Multiplex 
PCR Master Mix, 2,5 μl of Nextera XT primers 1 and 2 and 2,5 μl of DNase free water. The 
PCR cycle was initiated with an activation step of 15 minutes at 95°C followed by 15 cycles of 
denaturation for 30 seconds at 95°C, annealing for 30 seconds at 55°C and extension for 30 
seconds at 72°C. A final extension at 72°C was performed for 5 minutes. The PCR product 
from this second step of PCR was purified in the same way as before using the Agencourt 
AMPure XP reagent. 
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The concentrations of the DNA products were precisely measured with the use of Qubit 
Fluorometric Quantitation. Moreover, the quality and size of the samples were confirmed 
with the use of the Agilent high sensitivity DNA assay kit (Ref. 5067-4626). Samples were 
normalized within a similar range of concentrations so 1 μl of each sample was added to the 
final library pool which was used for sequencing. 
 
Sequencing of TCR library pool 
For the sequencing of the TCR amplicons the Illumina MiSeq chemistry V3 was used and a 
paired end 300 cycle run was performed following the manufacturer’s instructions. Briefly, 
the prepared library was diluted to a final concentration of 4nM. The library was denatured 
by mixing 5 μl with 5 μl of 0,2N NaOH, vortexing, spinning and incubating for 5 minutes at 
RT. 990 μl of prechilled hybridization buffer (HT1) was added to obtain 1 ml of 20 pM 
denatured library. This was further diluted to 12 pM by adding 240 μl of HT1 to 360 μl of 20 
pM denatured library. Finally, a PhiX control of 5% spike-in was used as a control for the 
Illumina sequencing.  
 
Bioinformatical analysis of MiSeq sequencing results 
For the comprehensive analysis of the large amount of reads obtained from the sequencing 
of TCR the use of bioinformatic tools was necessary. First, sequence reads were evaluated 
for their quality with the use of PRINSEQ-lite and PRINSEQ-graphs (v0.20.4) (Schmieder & 
Edwards 2011). Next, paired sequence reads were interleaved and filtered for their quality 
with the use of the sequence processing utilities “interleave_pairs” and “filter_by_quality” 
found in seq_crumbs (https://bioinf.comav.upv.es/seq_crumbs/). Read pairs were required 
to have a minimum quality score of 25. Those read pairs that met this requirement were 
merged over their overlapping sequences in order to obtain complete sequences of our 
target region with the use of FLASH (v1.2.9) (Magoč & Salzberg 2011).  
MiXCR (v1.8.1) was used to align the obtained sequences to reference V, D and J genes of T 
cell receptors in order to identify the genes present in the samples. Then, identical CDR3 
sequences are identified and grouped in clonotypes. All this information can finally be 
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exported into a tab-delimited and understandable text file (Bolotin et al. 2015). Afterwards, 
the R package tcR was used for advanced data analysis on the files obtained from MiXCR 
(Nazarov et al. 2015). tcR allowed the comparison of TCR repertoire among several samples 
and the calculation of the inverse simpson index as an indicator of diversity. 
 
Statistical analysis 
Statistical analyses were conducted using Graphpad Prism 5. In publication I, multiple sample 
comparisons were done by Kruskal–Wallis test followed by Dunn multiple comparison test. 
In publication II, non-parametric Mann-Whitney test was used for comparison of means. In 
publication III, associations between HLA-allele expression and outcome were assessed using 
Chi-square test with Bonferroni correction for multiple tests. Associations between TCR 
diversity and outcome, Ct value and others were determined using Mann-Whitney test.   
The levels of significance are interpreted as follows: NS (not significant) p>0,05, *p≤0,05, 
**p≤0,01, ***p≤0,001, and ****p≤0,0001. 
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